<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Orphanet J Rare Dis</journal-id><journal-id journal-id-type="iso-abbrev">Orphanet J Rare Dis</journal-id><journal-title-group><journal-title>Orphanet Journal of Rare Diseases</journal-title></journal-title-group><issn pub-type="epub">1750-1172</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40410905</article-id><article-id pub-id-type="pmc">PMC12101001</article-id><article-id pub-id-type="publisher-id">3782</article-id><article-id pub-id-type="doi">10.1186/s13023-025-03782-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Lipidomic profiling of the cerebrospinal fluid in moyamoya angiopathy patients</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Potenza</surname><given-names>Antonella</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Gorla</surname><given-names>Gemma</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Carrozzini</surname><given-names>Tatiana</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pollaci</surname><given-names>Giuliana</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dei Cas</surname><given-names>Michele</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Acerbi</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Vetrano</surname><given-names>Ignazio G.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ferroli</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Canavero</surname><given-names>Isabella</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Paroni</surname><given-names>Rita</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rifino</surname><given-names>Nicola</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bersano</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6751-5031</contrib-id><name><surname>Gatti</surname><given-names>Laura</given-names></name><address><email>laura.gatti@istituto-besta.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05rbx8m02</institution-id><institution-id institution-id-type="GRID">grid.417894.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0707 5492</institution-id><institution>Laboratory of Neurobiology and UCV, Neurology IX Unit, </institution><institution>Fondazione IRCCS Istituto Neurologico Carlo Besta, </institution></institution-wrap>20133 Milan, Italy </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00wjc7c48</institution-id><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution>Department of Pharmacological and Biomolecular Sciences, </institution><institution>Universit&#x000e0; degli Studi di Milano, </institution></institution-wrap>20122 Milan, Italy </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00wjc7c48</institution-id><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution>Clinical Biochemistry and Mass Spectrometry Lab, Department of Health Sciences, </institution><institution>Universit&#x000e0; degli Studi di Milano, </institution></institution-wrap>20132 Milan, Italy </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05rbx8m02</institution-id><institution-id institution-id-type="GRID">grid.417894.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0707 5492</institution-id><institution>Neurosurgical Unit, </institution><institution>Fondazione IRCCS Istituto Neurologico Carlo Besta, </institution></institution-wrap>20133 Milan, Italy </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03ad39j10</institution-id><institution-id institution-id-type="GRID">grid.5395.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 3729</institution-id><institution>Department of Translational Research and New Technologies in Medicine and Surgery, </institution><institution>University of Pisa, </institution></institution-wrap>56126 Pisa, Italy </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03ad39j10</institution-id><institution-id institution-id-type="GRID">grid.5395.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 3729</institution-id><institution>Neurosurgery Unit, </institution><institution>Pisa University Hospital, </institution></institution-wrap>56126 Pisa, Italy </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00wjc7c48</institution-id><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution>Department of Biomedical Sciences for Health, </institution><institution>Universit&#x000e0; degli Studi di Milano, </institution></institution-wrap>20122 Milan, Italy </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><elocation-id>243</elocation-id><history><date date-type="received"><day>23</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>9</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Moyamoya angiopathy (MA) is a rare cerebrovascular disorder which can occur in both children and young adults, characterized by progressive occlusion of the intracranial carotid arteries, leading patients to ischemic and haemorrhagic strokes. Despite decades of research, the mechanisms underlying MA remain poorly clarified and current gaps in the understanding of pathogenesis have hampered the development of suitable preventive strategies and therapeutic options. Moreover, clinically approved biomarkers for MA patients&#x02019; stratification are missing. The unknown pathophysiology and the lack of reliable biomarkers prompted us to investigate cerebrospinal fluid (CSF) lipidome through state-of-the-art lipidomics. </p></sec><sec><title>Methods</title><p id="Par2">Intraoperative CSF from a subgroup of MA patients in comparison to age/sex matched controls (CTRL) was analysed through LC&#x02013;MS/MS, by an untargeted lipidomic approach. Receiver operating characteristic (ROC) curve and simple linear regression analyses were performed for diagnostic use. We searched for simultaneously altered lipids in plasma and CSF of MA patients.</p></sec><sec><title>Results</title><p id="Par3">Overall, we observed a significant increase of sphingolipids (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) and phospholipids (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) in MA CSF. A partial least squares discriminant analysis clearly separated MA and CTRL by 64% on Principal Component 1. We identified lipid classes (n&#x02009;=&#x02009;12) with a Variance Importance in Projection score&#x02009;&#x02265;&#x02009;1.5, within those lipids highly correlated with MA (n&#x02009;=&#x02009;70). A significant increase in acylcarnitines, sphingolipids (sphingomyelins and ceramides), phospholipids (lysophosphatidylcholines; phosphatidylcholines; phosphatidylethanolamines; ether-phosphatidylethanolamines; ether-phosphatidylcholines) and cholesterol esters was found by multivariate and univariate analyses. Monoacylglycerols were the only lipid class displaying a markedly significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) decrease in CSF of MA patients as compared to CTRL subjects. The ROC curve and simple linear regression analysis identified 10 out of 12 lipid classes as reliable MA biomarkers, mainly dealing with phospholipids. We then compared current and previous data on plasma lipidomic profile. The discriminant analysis returned n&#x02009;=&#x02009;175 (in plasma) and n&#x02009;=&#x02009;70 (in CSF) simultaneously altered lipids respectively, and phosphatidylcholines (n&#x02009;=&#x02009;10) resulted as commonly decreased in plasma and increased in CSF.</p></sec><sec><title>Conclusions</title><p id="Par4">Our findings highlighted a strong pro-inflammatory environment in MA CSF. These preliminary hallmarks could be helpful to decipher the complex MA pathogenesis, by supplying candidate biomarkers for patient stratification.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13023-025-03782-5.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Moyamoya</kwd><kwd>CSF</kwd><kwd>Plasma</kwd><kwd>Lipidomics</kwd><kwd>Phospholipids</kwd><kwd>Sphingolipids</kwd><kwd>Phosphatidylcholines</kwd><kwd>Inflammation</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003196</institution-id><institution>Ministero della Salute</institution></institution-wrap></funding-source><award-id>RF-2019-12369247</award-id><award-id>RRC 2018-2023</award-id><award-id>RCR-2021-23671214</award-id><award-id>PNRR-MR1-2022-12376618</award-id><principal-award-recipient><name><surname>Bersano</surname><given-names>Anna</given-names></name><name><surname>Gatti</surname><given-names>Laura</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale (INSERM) 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec2"><title>Background</title><p id="Par57">Moyamoya angiopathy (MA) is an uncommon non-atherosclerotic cerebrovascular disease, characterized by progressive stenosis of the terminal internal carotid artery and its proximal branches, and formation of hazy collateral vessels at the base of the brain. The main clinical manifestations of MA are recurrent ischemic or haemorrhagic strokes and cognitive impairment, which can occur in both children and young adults [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Despite decades of research, the etiology and pathophysiological mechanisms underlying MA remain poorly clarified. Previous studies have highlighted the potential involvement of inflammation as a cause or progressive factor of MA, although the role of inflammation has not been rigorously explored [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Inflammatory processes have been suggested to instigate or exacerbate this rare condition, particularly in pediatric patients [<xref ref-type="bibr" rid="CR6">6</xref>]. MA is also emerging as an immune-related angiopathy, since an increasing number of reports describes the development of MA associated with infection or autoimmune disorders [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Several studies have identified a variety of autoimmune diseases associated to MA [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Besides, recent reports suggested that a more aggressive MA course is associated with the presence of thyroid autoantibodies [<xref ref-type="bibr" rid="CR11">11</xref>]. Together, this growing body of molecular and clinical evidence points towards immune-related responses as second hits to trigger MA onset and may hint at therapeutic opportunities. </p><p id="Par58">Current gaps in the understanding of disease pathogenesis have hampered the development of suitable preventive strategies and therapeutic options. Surgical revascularization, including superficial temporal artery (STA) to middle cerebral artery bypass (MCA), has been proven as an effective treatment to prevent subsequent strokes of MA patients [<xref ref-type="bibr" rid="CR12">12</xref>]. The prevalence of MA varies widely among ethnic groups, thus genetic factors have been implicated in disease development [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Specifically, a high prevalence of MA patients has been reported among the descendants belonging to East Asian countries, of whom the three most common are Japan, Korea and China. The estimated prevalence of MA in Japan is 10.5/100,000 individuals and the incidence rate is 0.94/100,000; conversely, the incidence rate is almost 10-fold lower accounting for 0.09/100,000 individuals in Western regions, including North America [<xref ref-type="bibr" rid="CR15">15</xref>]. Additionally, the incidence of MA in female subjects has been reported to be higher than that in males. Furthermore, a bimodal age distribution has been described is MA patients, referring to a highest peak observed at 45&#x02013;49 years and a smaller peak observed at 5&#x02013;9 years [<xref ref-type="bibr" rid="CR16">16</xref>]. The main susceptibility gene variant identified in East Asian patients encodes for the ubiquitin-ligase Ring Finger Protein 213 (RNF213) [<xref ref-type="bibr" rid="CR17">17</xref>]. So far, no animal or cellular preclinical model accurately recapitulates the pathological changes observed in vascular intimal hyperplasia of MA patients [<xref ref-type="bibr" rid="CR18">18</xref>]. Moreover, there are no clinically approved biomarkers for distinguishing among the different subtypes of MA.</p><p id="Par59">The previous investigations aimed at biomarker discovery mainly addressed peripheral blood, which may not reflect the real pathological changes of MA cerebral vessels. Since the challenging sampling of cerebral artery specimens for transcriptomic studies, other ultrasensitive techniques were recently carried out for molecular profiling of circulating biomarkers [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. In this regard, multi-omic approaches may turn out to be crucial in patients&#x02019; risk stratification and precision medicine, allowing for the selection and customization of medical treatment based on individual signatures [<xref ref-type="bibr" rid="CR22">22</xref>]. Despite numerous findings in the proteomics and metabolomics field [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>], very little is known about changes in the lipid composition in patients&#x02019; circulating fluids, although it has been already reported that RNF213 is involved in lipid metabolism [<xref ref-type="bibr" rid="CR28">28</xref>]. Lipids are a significant part of the neural molecular environment, constituting approximately 50% of the dry weight of the brain [<xref ref-type="bibr" rid="CR29">29</xref>]. They are essential for proper brain function, being required for axon growth and potentiation, membrane trafficking, myelin formation, synaptogenesis and accounting for critical components of cell membranes [<xref ref-type="bibr" rid="CR30">30</xref>]. It is not surprising that changes that affect brain lipid metabolism and/or its delicate vascular network, have profound implications in tissue homeostasis and have been implicated as underlying mechanisms for many cerebrovascular diseases. The alterations in the MA vasculature induced by ischemic insult and oxygen deprivation can cause the loss of astrocytes and microglia, reduce neuronal function and increase neuroinflammation. These changes may be coupled with intense lipid remodeling in CSF, and affect also cholesterol metabolism, which is essential for neuronal growth and survival since they need cholesterol to repair and build more membranes.</p><p id="Par60">Recently, a lipidomic analysis of cerebral arteries in MA and intracranial atherosclerotic disease patients identified distinct lipid species for distinguishing between the two conditions [<xref ref-type="bibr" rid="CR31">31</xref>]. Our previous gene expression analyses of MA pathological cerebral vessels also underlined the relevance of specific biomarkers for patient&#x02019;s stratification, as well as a novel potential therapeutic target for MA care [<xref ref-type="bibr" rid="CR32">32</xref>]. However, the poor availability and difficulty in collecting arterial tissue specimens prompted us to search for valuable biomarkers in circulating fluids, mainly plasma and CSF. We previously performed an untargeted lipidomic analysis showing a cumulative depletion of lipid asset in plasma of MA as compared to healthy donors [<xref ref-type="bibr" rid="CR33">33</xref>]. These promising but preliminary results encouraged us to investigate cerebrospinal fluid (CSF) as an alternative biomarker source. The identification of changes in metabolic profiles, providing valuable biomarkers and shedding light on mechanisms of diseases could have a crucial role in patients&#x02019; risk stratification and precision medicine, allowing for the selection and customization of medical treatment based on individual metabolic profiles. In this pilot study, we aimed to elucidate the MA CSF lipidome, by identifying altered lipids in a representative sample of a typical Caucasian MA population. We consider that a better understanding of specific lipid changes and their eventual correlation with clinical outcomes could help to guide patients&#x02019; stratification approaches, with a possible impact also in the prevention of MA evolution.</p></sec><sec id="Sec3"><title>Methods</title><sec id="Sec4"><title>Cohort selection and sampling</title><p id="Par61">This was an observational study conducted on MA patients, diagnosed following the literature criteria [<xref ref-type="bibr" rid="CR34">34</xref>]. The full methodology of the study has been previously reported [<xref ref-type="bibr" rid="CR35">35</xref>]. From the original population of 160 patients, consecutively enrolled between November 2014 and December 2022 at the Neurology IX Unit of the Fondazione IRCCS Istituto Neurologico &#x0201c;C. Besta&#x0201d; (Italy, Milan), a subgroup of five adult Caucasian patients was selected, exclusively based on CSF availability and demographic/clinical features typical of MA cohort. CSF samples were obtained after the neurological insult that determined the STA-MCA neurosurgical bypass, according to European Stroke Organisation (ESO) Guidelines on moyamoya angiopathy [<xref ref-type="bibr" rid="CR36">36</xref>]. The study design was approved by the Ethics Committee of the Fondazione IRCCS Istituto Neurologico &#x0201c;C. Besta&#x0201d; of Milan (GEN-O-MA clinical study, report no. 12, 10/01/2014). Informed written consent for study participation and sample collection from all patients and controls were mandatory for study inclusion. Demographic and clinical characteristics, including cerebrovascular risk factors, were collected. MA was classified into bilateral or unilateral types as observed on conventional angiography. Diagnosis of ischemic or haemorrhagic stroke was confirmed by computerized tomography scan and magnetic resonance imaging. The MA severity was assessed by Suzuki and modified Rankin scale according to standard clinical practice and international guidelines [<xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>]. A population of five adult Caucasian subjects admitted to our Institution and suffering from MA-unrelated hemodynamic insufficiency, secondary to arterial stenosis due to atherosclerotic diseases or due to isolated intracranial aneurysms, was collected as control group (CTRL). Control CSF was sampled during surgical procedure, in patients undergoing STA-MCA bypass for hemodynamic cerebrovascular insufficiency or a craniotomy to clip intracranial aneurysm in the anterior circulation, mostly MCA or anterior communicating artery. No further procedures apart from the surgical treatment were necessary to obtain CSF. A multidisciplinary team discussed surgical indications in all the patients, both MA and CTRL. CSF was collected from MA patients and CTRL subjects from cisternal spaces, mainly sylvian fissure, after arachnoid incision, in compliance with ethical regulations of ESO Guidelines on moyamoya angiopathy [<xref ref-type="bibr" rid="CR36">36</xref>]. After collection, samples were briefly centrifuged to remove any cellular debris and stored in aliquots at &#x02212;&#x02009;80&#x000a0;&#x000b0;C. Twenty-four milliliters of peripheral blood were collected in tubes containing EDTA (Vacuette&#x000ae;, Preanalitica s.r.l., Caravaggio, Italy). Blood samples were analyzed for levels of triglycerides (TG), total cholesterol (CHOL) and high-density lipoprotein (HDL) CHOL by standard clinical laboratory methods; low-density lipoprotein (LDL) CHOL concentrations were estimated as CHOL&#x02014;(HDL&#x02009;+&#x02009;TG/5). After 10 min at 200 g centrifugation, plasma was stored in aliquots at &#x02212;&#x02009;80&#x000a0;&#x000b0;C.</p></sec><sec id="Sec5"><title>Chemicals and reagents</title><p id="Par62">The chemicals acetonitrile, 2-propanol, methanol, chloroform, formic acid, ammonium acetate, ammonium formate and dibutylhydroxytoluene (BHT) were purchased from Sigma-Aldrich (St. Louis, MO, USA). All aqueous solutions were prepared using purified water at a Milli-Q grade (Burlington, MA, USA).</p></sec><sec id="Sec6"><title>Untargeted lipidomics</title><p id="Par63">CSF and plasma were diluted with water (1:2 CSF, 1:4 plasma v/v) and lipids were extracted by a mixture of methanol/chloroform (850 &#x000b5;L, 2:1, v/v). The samples were extracted with an oscillator thermo-mixer (60 min, 1000 rpm, 4&#x000a0;&#x000b0;C). After centrifugation (25 min at 13400 rpm), the organic phase was evaporated under a stream of nitrogen. The residues were dissolved in 100 &#x000b5;L of methanol + 0.1% BHT and withdrawn in a glass vial. Extraction and analysis performances were checked by the use of a preconstituted internal standards mix (Equisplash Lipidomix, 150 ng per sample, Avanti Polar, Alabaster, AL, USA). The extracts were analysed by LC-MS/MS consisting of a Shimadzu UPLC coupled with a Triple TOF 6600 Sciex (Concord, ON, CA) [<xref ref-type="bibr" rid="CR33">33</xref>]. All samples were analyzed in duplicate in positive and negative electrospray ionization. Spectra were contemporarily acquired by full-mass scan from 200 to 1500 m/z and top-20 data-dependent acquisition from 50 to 1500 m/z. Declustering potential was fixed to 50 eV, and the collision energy was 35&#x02009;&#x000b1;&#x02009;15 eV. The chromatographic separation was reached on a reverse-phase Acquity CSH C18 column 1.7 &#x003bc;m, 2.1 &#x000d7; 100 mm (Waters, Franklin, MA, USA) by a gradient between (A) water/acetonitrile (60:40) and (B) 2-propanol/acetonitrile (90:10), both containing 10 mM ammonium acetate and 0.1% of formic acid.</p></sec><sec id="Sec7"><title>LC-HR-MS data processing</title><p id="Par64">The spectra deconvolution, peak alignment, and sample normalization were attained using MS-DIAL [<xref ref-type="bibr" rid="CR38">38</xref>]. MS and MS/MS tolerance for peak profile was set to 0.01 and 0.05 Da, respectively. Identification was achieved matching spectra with LipidBlast database or in-house built mass spectral library. Intensities of analytes were normalized by Lowless algorithm and those with a CV% superior to 30% in the QC pool sample were excluded. The lipid classes considered were acylcarnitines (ACar), cholesterol (chol), cholesterol esters (CE), monoacylglycerols (MAG), diacylglycerols (DAG), triacylglycerols (TAG); dihydroceramides (DHCer), ceramides (Cer), hexosylceramides (HexCer), lactosylceramides (LacCer), globotriaosylceramide (Gb3), sulfatides (SULF), gangliosides (GM3), sphingomyelins (SM), lysophosphatidylcholines (LPC), lysophosphatidylethanolamines (LPE), phosphatidylcholines (PC), phosphatidylethanolamines (PE), phosphatidylinositoles (PI) and plasmalogens &#x02013; that are ether linked phosphatidylcholines (EtherPC) and vinyl linked phosphatidylethanolamines (EtherPE). The lipids are indicated throughout the paper by their total number of carbon atoms and degree of unsaturation (i.e. PC 40:2) or eventually specifying the acyl chains detected (i.e. PC 18:0/18:1). The study raw data supporting lipidomic reported results can be found in the public repository MetaboLights [<xref ref-type="bibr" rid="CR39">39</xref>].</p></sec><sec id="Sec8"><title>Statistical analyses</title><p id="Par65">Graphs and statistical analyses were prepared with GraphPad Prism 8.0, and with MetaboAnalyst5.0 [<xref ref-type="bibr" rid="CR40">40</xref>]. Statistical significance was evaluated by comparing ranks with non-parametric Mann-Whitney U test and Fisher&#x02019;s exact test. Multivariate analysis partial least squares discriminant analysis (PLS-DA) was performed to increase the group separation and investigate the variables with a high Variance Importance in Projection score (VIP &#x0003e; 1.5). <italic>P</italic> &#x0003c;0.05 was considered statistically significant. <italic>P</italic> values are schematized as follows: * &#x0003c;&#x02009;0.05; ** &#x0003c;&#x02009;0.01; *** &#x0003c;&#x02009;0.001. Data are shown as mean &#x000b1; SD. To explore factors affecting the lipid composition within MA patients, receiver operating characteristic (ROC) curves and simple linear regression model were used. Sensitivity and specificity were defined to estimate the performances of the candidate lipid to discriminate between MA patients and CTRL. The authors were blinded to the experimental protocol while performing the experiments and the statistical calculations.</p></sec></sec><sec id="Sec9"><title>Results and discussion</title><sec id="Sec10"><title>Demographic characteristics of the study cohorts</title><p id="Par66">According to the GEN-O-MA project and ESO Guidelines [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], a small but representative subgroup of subjects was enrolled for the present study, since untargeted lipidomics requires a very homogeneous group that would allow identifying any potetial difference in lipidome profiles between MA patients and CTRL subjects. Specifically, we included five MA Caucasian patients, based on CSF availability and demographic/clinical features typical of our MA cohort (Caucasian, females, mean age of 47 years, bilateral MA presentation) [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Of note, these characteristics are precisely representative of the whole MA population in Western countries, which is a relevant aspect considering the rarity of the disease [<xref ref-type="bibr" rid="CR42">42</xref>]. We summarized MA patient information in Table <xref rid="Tab1" ref-type="table">1</xref>, by reporting the mean age (&#x000b1; SD); Sex (female %); cerebrovascular disease (CVD) type (hemorrhagic stroke, ischemic stroke, transient ischemic attack TIA); National Institutes of Health Stroke Scale (0&#x02013;5; 6&#x02013;10); MA presentation (Unilateral or Bilateral); Suzuki grading (I&#x02013;III; IV&#x02013;VI); modified Rankin Scale (0&#x02013;1; 2&#x02013;3). The patients (100% females) had a mean age of 45.56&#x02009;&#x000b1;&#x02009;4.2 years (range 38.8&#x02013;49.6). The disease presented with a haemorrhagic stroke in 40% of patients, an ischemic event in 40% and a TIA in 20% of the cases. Five control patients (100 % females; mean age of 66.2 years, range 44.0&#x02013;76.0) underwent conventional catheter digital subtraction angiography and morphological imaging by MRI, likewise MA patients. Computerized tomography scan and MRI showed an ischemic stroke in three controls out of five (corresponding to a percentage of 60%) and a TIA in one control subject out of five (corresponding to a percentage of 20%), representing patients with hemodynamic cerebrovascular impairment, deeply distinct and unrelated from MA. The hemorrhagic phenotype was reported in one control patient out of five (corresponding to a percentage of 20%), who exhibited an intracranial aneurysm with previous small bleeding (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Participant characteristics<sup>a</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left">MA</th><th align="left">CTRL</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">N</td><td align="left"/><td align="left">5</td><td align="left">5</td><td align="left"/></tr><tr><td align="left">Mean age (y&#x02009;&#x000b1;&#x02009;SD)</td><td align="left"/><td align="left">45.56&#x02009;&#x000b1;&#x02009;4.2</td><td align="left">66.2&#x02009;&#x000b1;&#x02009;12.77</td><td align="left">0.095 (ns)</td></tr><tr><td align="left">Sex (% F)</td><td align="left"/><td align="left">100%</td><td align="left">100%</td><td align="left">1 (ns)</td></tr><tr><td align="left" rowspan="3">CVD type</td><td align="left">HS</td><td align="left">40%</td><td align="left">20%</td><td align="left">1 (ns)</td></tr><tr><td align="left">IS</td><td align="left">40%</td><td align="left">60%</td><td align="left">1 (ns)</td></tr><tr><td align="left">TIA</td><td align="left">20%</td><td align="left">20%</td><td align="left">1 (ns)</td></tr><tr><td align="left" rowspan="2">NIHSS</td><td align="left">0&#x02013;5</td><td align="left">80%</td><td align="left">na</td><td align="left">#</td></tr><tr><td align="left">6&#x02013;10</td><td align="left">20%</td><td align="left">na</td><td align="left">#</td></tr><tr><td align="left" rowspan="2">MA presentation</td><td align="left">U</td><td align="left">0%</td><td align="left">na</td><td align="left">#</td></tr><tr><td align="left">B</td><td align="left">100%</td><td align="left">na</td><td align="left">#</td></tr><tr><td align="left" rowspan="2">Suzuki grading</td><td align="left">I&#x02013;III</td><td align="left">40%</td><td align="left">na</td><td align="left">#</td></tr><tr><td align="left">IV&#x02013;VI</td><td align="left">60%</td><td align="left">na</td><td align="left">#</td></tr><tr><td align="left" rowspan="2">mRS</td><td align="left">0&#x02013;1</td><td align="left">100%</td><td align="left">100%</td><td align="left">1 (ns)</td></tr><tr><td align="left">2&#x02013;3</td><td align="left">0</td><td align="left">0</td><td align="left">#</td></tr><tr><td align="left">CHOL (mg/dl)</td><td align="left"/><td align="left">168.6</td><td align="left">217.7</td><td align="left">0.571 (ns)</td></tr><tr><td align="left">TG (mg/dl)</td><td align="left"/><td align="left">102.2</td><td align="left">176.3</td><td align="left">0.589 (ns)</td></tr><tr><td align="left">HDL (mg/dl)</td><td align="left"/><td align="left">40</td><td align="left">35</td><td align="left">0.467 (ns)</td></tr><tr><td align="left">LDL (mg/dl)</td><td align="left"/><td align="left">92.25</td><td align="left">92</td><td align="left">0.999 (ns)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Demographic, clinical, and neuroradiological features of MA patients and control subjects. Statistical significance was evaluated by comparing ranks with Mann&#x02013;Whitney U test or Fisher&#x02019;s exact test. B, bilateral; CHOL, total cholesterol; CTRL, controls; CVD, cerebrovascular disease; F, female; HDL, high-density lipoprotein&#x02014;cholesterol; HS, haemorrhagic stroke; IS, ischemic stroke; LDL, low-density lipoprotein&#x02014;cholesterol; MA, moyamoya angiopathy; mRS, modified rankin scale; N, number of subjects; na, not available; NIHSS, national institutes of health stroke scale; ns, not significant; TIA, transient ischemic attack; TG, triglycerides; U, unilateral; y, years</p></table-wrap-foot></table-wrap></p><p id="Par67">No statistical difference has been evidenced when comparing peripheral blood lipid levels determined by standard clinical laboratory methods, in MA patients and CTRL (CHOL; HDL; LDL; TG; Table <xref rid="Tab1" ref-type="table">1</xref>).</p></sec><sec id="Sec11"><title>Increase of the overall lipid content in CSF of MA patients.</title><p id="Par68">A total of n&#x02009;=&#x02009;623 different lipids were identified and quantified in CSF from MA and CTRL populations, by an untargeted lipidomic approach. The overall CSF lipid content of MA patients was higher in comparison to CTRL, although not statistically significant (Fig. <xref rid="Fig1" ref-type="fig">1</xref>A).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Overall CSF lipid content. <bold>A</bold> Total CSF lipid content in MA patients and in CTRL subjects with unrelated cerebrovascular diseases <bold>B</bold> Lipid classes significantly increased in CSF of MA patients. Statistical significance is evaluated by comparing ranks with Mann&#x02013;Whitney U test. <italic>P</italic> values are schematized as follows: *&#x02009;&#x0003c;&#x02009;0.05; ***&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="13023_2025_3782_Fig1_HTML" id="MO1"/></fig></p><p id="Par69">Among the most altered lipid categories, we found the sphingolipids (Ceramides, Cer) and phospholipids (i.e., LPC; PC; PE). In particular, we observed significant increases for Cer (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05), LPC (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05), PC (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05) and PE (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.001; Fig. <xref rid="Fig1" ref-type="fig">1</xref>B) classes. A list of the main lipid classes emerging from our analysis was shown (Table <xref rid="Tab2" ref-type="table">2</xref>). Of note, although characterized by a different time lapse (25 &#x000b1; 13 months) between disease onset and CSF sampling during the neurosurgical procedure, the lipidome profile of our MA cohort is quite homogeneous (see Additional File <xref rid="MOESM1" ref-type="media">1</xref>). Moreover, when we performed appropriate statistical analyses (non-parametric Mann-Whitney U test), to evaluate the profile of specific CSF lipid classes/species in MA patients in relation to CVD type (HS vs IS/TIA), Suzuki grading (I&#x02013;III vs. IV&#x02013;VI) and NIHSS (0&#x02013;5 vs. 6&#x02013;10), we did not find any statistically significant difference between the analysed subgroups (see Additional Files <xref rid="MOESM1" ref-type="media">2</xref>, <xref rid="MOESM1" ref-type="media">3</xref>, <xref rid="MOESM1" ref-type="media">4</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Nomenclature of CSF lipid classes/species* emerging from lipidomics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">ACar</th><th align="left">Acylcarnitines</th><th align="left">MAG</th><th align="left">Monoacylglycerols</th></tr></thead><tbody><tr><td align="left">Cer 18:0</td><td align="left">Ceramide 18:0</td><td align="left">LPC</td><td align="left">Lysophosphatidylcholines</td></tr><tr><td align="left">CE 22:4</td><td align="left">Cholesterol ester 22:4</td><td align="left">PC</td><td align="left">Phosphatidylcholines</td></tr><tr><td align="left">DAG</td><td align="left">Diacylglycerols</td><td align="left">PE</td><td align="left">Phosphatidylethanolamines</td></tr><tr><td align="left">Ether PC</td><td align="left">Phosphatidylcholine Ethers</td><td align="left">SM</td><td align="left">Sphingomyelins</td></tr><tr><td align="left">Ether PE</td><td align="left">Phosphatidylethanolamine Ethers</td><td align="left">TAG</td><td align="left">Triacylglycerols</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>Cer 18:0 and CE 22:4 were included in Table because were found as single lipid altered species of their respective lipid classes</p></table-wrap-foot></table-wrap></p><p id="Par70">Ceramides, beyond being an essential constituent of cytomembrane, play a key role as signaling mediators in many cell processes and stress responses. Interestingly, a marked relation has been documented between ceramides and cerebrovascular diseases [<xref ref-type="bibr" rid="CR43">43</xref>]. PC act as principal components of cell membranes, playing a role in cell signalling and ameliorating neuronal damage under inflammatory stress, by re-establishing plasticity of neural stem cells [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. LPC, as well as PC, are bioactive compounds associated with oxidative stress and inflammatory processes, with a potential effect in preventing ischemic injury or neuronal death in patients with stroke [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Interestingly, an untargeted metabolomic approach recently carried out has been able to identify a distinct metabolite expression, mostly dealing with LPC, in serum samples from MA patients when compared to controls [<xref ref-type="bibr" rid="CR27">27</xref>]. Specifically, LPC 16:1-2 expression was found as significantly lower in ischaemic MA patients than in healthy controls. The LPC-enriched CSF lipid content reported in the present study might counterbalance the corresponding LPC depletion identified in plasma samples of the same MA cohort [<xref ref-type="bibr" rid="CR33">33</xref>].</p></sec><sec id="Sec12"><title>Differential lipid analysis</title><p id="Par71">A PLS-DA was performed to identify deregulated lipids associated with MA (Fig. <xref rid="Fig2" ref-type="fig">2</xref>A). This analysis clearly separated MA patients and CTRL subjects by 64% on Principal Component 1 (PC1). The PC1 represents the new dimension in which the initial variables are compressed and depicts the maximum of the separation that can be reached within these clusters and variables. The Variance Importance in Projection (VIP) scores derived from PLS-DA were used for ranking the discriminating features, taking a cut-off value &#x02265; 1.5. Those lipid species (<italic>n</italic> = 70) with a VIP &#x02265; 1.5 that significantly contributed to the separation of MA patients and CTRL are visualized by a heatmap and ordered according to their lipid classes (Fig. <xref rid="Fig2" ref-type="fig">2</xref>B). Fig. <xref rid="Fig2" ref-type="fig">2</xref>C shows a univariate analysis with the twelve lipid classes displaying significant modulations due to the disease. Features exhibiting VIP &#x02265; 1.5 and variance <italic>p</italic>-value &#x02264; 0.05 were selected as significantly differentially abundant lipids. Of note, Cer 18:0 and CE 22:4 are the only VIP lipids found in their corresponding lipid classes (i.e., sphingolipids and neutral lipids), and therefore the boxes represent the trend of these single species.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>CSF untargeted lipidomics. CSF lipid alteration in MA patients (n&#x02009;=&#x02009;5) in comparison to age and sex matched controls with unrelated cerebrovascular diseases (CTRL, n&#x02009;=&#x02009;5). <bold>A</bold> Discriminant analysis (score plot) of the lipidome in MA and CTRL subjects. The axes are ranked according to their importance in the group discrimination. In the x-axis, component 1 (PC1, 64%) represents the maximum of the separation that can be reached within these clusters and variables, whereas, in the y-axis, component 2 (PC2, 12.8%) represents the direction that contains the most remaining variance. <bold>B</bold> Heatmap of the top 70 significantly altered lipid species highly correlated with the disease, chosen within those with a Variance Importance in Projection (VIP) score&#x02009;&#x0003e;&#x02009;1.5, and ordered by lipid classes, coded by different colors. Each horizontal row represents a molecular lipid; each vertical column represents a sample. The concentrations were autoscaled and log- transformed for visualization. The color code bar indicates the log of the fold change of the mean concentration for a given lipid. The color-scale differentiates values as high (red), average (white) and low (blue). <bold>C</bold> VIP lipid classes concentrations in MA and CTRL subjects. Boxplots represent the trends in lipid class concentrations in MA and CTRL patients, except for Cer 18:0 and CE 22:4 which are the only VIP lipids found in their classes and therefore the boxes represent the trend of these single species. The boxes represent data obtained in the range 25th-75th percentile; the line across the boxes indicates the median value; the lines above and below the boxes indicate extreme values (10th or 90th percentile). Outliers are displayed as separate points. Statistical significance is evaluated by comparing ranks with Mann&#x02013;Whitney U test. <italic>P</italic> values are schematized as follows: **&#x02009;&#x0003c;&#x02009;0.01; ***&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="13023_2025_3782_Fig2_HTML" id="MO2"/></fig></p><p id="Par72">The high sphingolipid/phospholipid content as well as the finding of pro-inflammatory lipid classes were confirmed by PCA. By evaluating both multivariate and univariate analyses, it has been found a particular increase in many phospholipids (PC, PE, LPC, Ether PC and Ether PE) and in Acylcarnitines (ACar; <italic>p&#x02009;</italic>&#x0003c;&#x02009;0.001). The increased levels of ACar among acute ischemic stroke patients indicate a major energy requirement due to a negative feedback from the brain hypoxic state [<xref ref-type="bibr" rid="CR48">48</xref>]. ACar are also related to the recovery of stroke [<xref ref-type="bibr" rid="CR49">49</xref>], and carnitines are associated with ischemic strokes [<xref ref-type="bibr" rid="CR50">50</xref>]. Moreover, a previous targeted metabolomic approach suggested a biomarker pattern including ACar for differential diagnosis of acute ischemic stroke [<xref ref-type="bibr" rid="CR51">51</xref>]. Higher plasma ACar levels were observed in individuals with an increased cardiovascular disease risk, as shown by a greater mitochondrial production of reactive oxygen species, which increase vascular inflammation [<xref ref-type="bibr" rid="CR52">52</xref>]. Ether-PC and ether-PE contain high amounts of arachidonic acid required for the biosynthesis of eicosanoids, bioactive lipids with a great role in inflammation. In hypertensive patients, a deficiency in plasma ether lipids has been demonstrated, specifically in ether-PC and ether-PE [<xref ref-type="bibr" rid="CR53">53</xref>]. Moreover, an accelerated PC turnover in macrophages promotes adipose tissue inflammation in obesity [<xref ref-type="bibr" rid="CR54">54</xref>]. Additionally, the role of LPC in promoting the release of inflammatory factors has been described in a wide range of diseases [<xref ref-type="bibr" rid="CR55">55</xref>], thus raising the hypothesis that LPC-targeting might be a valuable therapeutic approach for inflammation-related diseases, including MA. The observed Cer 18:0 increase is a worse condition in several neurological diseases, due to proinflammatory and neurodegenerative functions [<xref ref-type="bibr" rid="CR56">56</xref>]. Increased plasma levels of Cer (18:0) and SM have been implicated in insulin resistance, whereas inflammation may contribute to its long-term maintenance, especially in models of obesity-induced insulin resistance [<xref ref-type="bibr" rid="CR57">57</xref>]. SM is reported to be a biomarker of demyelination [<xref ref-type="bibr" rid="CR58">58</xref>], which is coherent with the occurrence of a myelin damage, observed in the white matter of MA patients [<xref ref-type="bibr" rid="CR59">59</xref>]. The impact of sphingolipids is evident in acute lung injury, or chronic lung pathologies such as cystic fibrosis and chronic obstructive pulmonary disease, where inflammation has a major role [<xref ref-type="bibr" rid="CR60">60</xref>]. CE in the human brain are sequestered as lipid droplets, primarily used for the transport and storage of CHOL [<xref ref-type="bibr" rid="CR61">61</xref>], a process occurring allosterically in response to surplus CHOL within the cell [<xref ref-type="bibr" rid="CR62">62</xref>]. CE are increased in several neurological disorders such as multiple sclerosis, Alzheimer&#x02019;s disease, brain injury, Huntington&#x02019;s disease and stroke [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Recently, a shotgun lipidomic analysis reported that CHOL was inefficiently converted to CE in the blood of cardiovascular disease patients [<xref ref-type="bibr" rid="CR65">65</xref>]. Interestingly, endogenously generated lipid mediators (branched FA esters of hydroxy FA) promote the resolution of inflammation and attenuate the microvascular and macrovascular complications of obesity and diabetes mellitus in chronic kidney disease [<xref ref-type="bibr" rid="CR66">66</xref>]. This evidence highlights novel opportunities for potential therapeutic intervention through the targeting of pro-resolution, rather than anti-inflammatory pathways.</p><p id="Par73">MAG was the only lipid class displaying a markedly significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) decrease in CSF of MA patients as compared to CTRL subjects (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C). MAG is a neutral lipid that is degraded to glycerol and fatty acids by MAG-lipase (MAGL), a proinflammatory enzyme with highest expression in brain [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>], where it constitutes the major source of arachidonic acid and proinflammatory prostaglandins [<xref ref-type="bibr" rid="CR69">69</xref>]. The marked decrease of MAG in MA CSF might result in induction of pro-inflammatory signals. Interestingly, MAGL inhibition protects against inflammation and lesions induced by ischaemia/reperfusion injury [<xref ref-type="bibr" rid="CR70">70</xref>]. Accordingly, inhibition of MAGL has emerged as an anti-inflammatory and protective option in several experimental models of chronic inflammatory diseases, by a mechanism that relies on a shift of lipid metabolism in inflammatory cells [<xref ref-type="bibr" rid="CR67">67</xref>].</p></sec><sec id="Sec13"><title>ROC and simple linear regression analysis of lipid biomarkers</title><p id="Par74">In order to determine whether these candidate CSF biomarkers could have any clinical utility as potential patient selection markers, we performed ROC curve and simple linear regression analysis for prospective follow-up and for diagnostic use. Twelve lipid classes showing significant alterations in CSF (i.e., with VIP&#x02009;&#x02265;&#x02009;1.5) between MA and CTRL subjects were selected for individual ROC analysis. According to ROC analysis, 10 out of 12 classes proved to be candidate diagnostic biomarker, since they displayed high sensitivity and specificity performances (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). All these 10 lipid classes presented area under the ROC curve (AUC) values higher than 0.9, and 7 out of 10 classes showed a perfect performance, by exhibiting an AUC&#x02009;=&#x02009;1. Specifically, 5 out of 9 lipid classes showing a significant increase in MA patients belonged to the category of phospholipids (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> and Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>ROC analysis of lipid biomarkers<sup>a</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Lipid class</th><th align="left">Trend</th><th align="left">AUC</th><th align="left"><italic>P</italic> value</th><th align="left">CI</th></tr></thead><tbody><tr><td align="left">ACar</td><td align="left"><bold>&#x02191;</bold></td><td align="left">1</td><td char="." align="char">0.009</td><td align="left">1.000&#x02013;1.000</td></tr><tr><td align="left">LPC</td><td align="left"><bold>&#x02191;</bold></td><td align="left">1</td><td char="." align="char">0.009</td><td align="left">1.000&#x02013;1.000</td></tr><tr><td align="left">PC</td><td align="left"><bold>&#x02191;</bold></td><td align="left">1</td><td char="." align="char">0.009</td><td align="left">1.000&#x02013;1.000</td></tr><tr><td align="left">PE</td><td align="left"><bold>&#x02191;</bold></td><td align="left">1</td><td char="." align="char">0.009</td><td align="left">1.000&#x02013;1.000</td></tr><tr><td align="left">EtherPC</td><td align="left"><bold>&#x02191;</bold></td><td align="left">1</td><td char="." align="char">0.009</td><td align="left">1.000&#x02013;1.000</td></tr><tr><td align="left">EtherPE</td><td align="left"><bold>&#x02191;</bold></td><td align="left">1</td><td char="." align="char">0.009</td><td align="left">1.000&#x02013;1.000</td></tr><tr><td align="left">MAG</td><td align="left"><bold>&#x02193;</bold></td><td align="left">1</td><td char="." align="char">0.009</td><td align="left">1.000&#x02013;1.000</td></tr><tr><td align="left">SM</td><td align="left"><bold>&#x02191;</bold></td><td align="left">0.96</td><td char="." align="char">0.016</td><td align="left">0.843&#x02013;1.000</td></tr><tr><td align="left">CE 22:4</td><td align="left"><bold>&#x02191;</bold></td><td align="left">0.92</td><td char="." align="char">0.028</td><td align="left">0.739&#x02013;1.000</td></tr><tr><td align="left">Cer 18:0</td><td align="left"><bold>&#x02191;</bold></td><td align="left">0.93</td><td char="." align="char">0.028</td><td align="left">0.739&#x02013;1.000</td></tr><tr><td align="left">DAG</td><td align="left"><bold>&#x02191;</bold></td><td align="left">0.52</td><td char="." align="char">0.917</td><td align="left">0.122&#x02013;0.918</td></tr><tr><td align="left">TAG</td><td align="left"><bold>&#x02191;</bold></td><td align="left">0.52</td><td char="." align="char">0.917</td><td align="left">0.135&#x02013;0.905</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Main lipid classes selected for individual receiver operating characteristic (ROC) curve analysis. The trend described by the analysis has been defined as enhanced (<bold>&#x02191;</bold>) or decreased (<bold>&#x02193;</bold>). P values and confidence interval (CI) values are reported. AUC, area under the ROC curve. Cer 18:0 and CE 22:4 are the only VIP lipids found in their classes and therefore they were reported as single species. The nomenclature of lipid classes/species was reported above (see Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>)</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>ROC analysis of phospholipid biomarker candidates. The performance of five lipid classes belonging to the phospholipid category (<bold>A</bold>&#x02013;<bold>E</bold>), showing significant alterations in CSF (i.e., with VIP&#x02009;&#x02265;&#x02009;1.5), for discriminating MA patients from CTRL subjects was evaluated by the area under the ROC curve (AUC) and by the determination of specificity (<italic>percentage of true negatives</italic>) and sensitivity (<italic>percentage of true positive).</italic> The nomenclature of lipid classes was reported above (see Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>)</p></caption><graphic xlink:href="13023_2025_3782_Fig3_HTML" id="MO3"/></fig></p><p id="Par75">A simple linear regression model assayed the five phospholipid classes showing VIP&#x02009;&#x02265;&#x02009;1.5 and exhibiting good performance after ROC analyses, to establish the reciprocal relationships among them (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Specifically, the expression levels of PC/LPC (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A) and LPC/ether PC (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B) increased proportionally in CSF of both MA patients and CTRL subjects. On the contrary, the relationships between PC/ether PC (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>C) and PE/ether PE (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>D) are directly proportional in CSF of MA patients but not in CTRL subjects. Other tested lipid classes showing linear correlation are shown in Additional File <xref rid="MOESM1" ref-type="media">5</xref>.<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Simple linear regression model. Statistically significant simple linear regression analyses of selected lipid classes that showed VIP&#x02009;&#x02265;&#x02009;1.5 in CSF of MA patients as compared to CTRL subjects; <bold>A</bold> PC/LPC; <bold>B</bold> LPC/ether PC; <bold>C</bold> PC/ether PC; <bold>D</bold> PE/ether PE; <bold>E</bold> PC/MAG. The nomenclature of lipid classes was reported above (see Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>)</p></caption><graphic xlink:href="13023_2025_3782_Fig4_HTML" id="MO4"/></fig></p><p id="Par76">As we reported above, MAG was the only lipid class displaying a markedly significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) decrease in CSF of MA patients as compared to CTRL subjects (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C). Interestingly, PC/MAG (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>E) were correlated by an inverse proportionality only in MA patients&#x02019; CSF. Overall, we can hypothesize that the peculiar and significant correlation between PC increase and MAG decrease in patient&#x02019;s CSF (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>E) could be suggestive of a MA-associated inflammatory environment.</p></sec><sec id="Sec14"><title>Discovery of lipids simultaneously altered in plasma and CSF of MA</title><p id="Par77">By comparing current and previous data on plasma lipidomic profile of the same population of MA patients, we found that in CTRL subjects the overall CSF lipid content was 3% of the overall plasma lipid content [<xref ref-type="bibr" rid="CR33">33</xref>]. Interestingly, in MA patients the CSF lipid content was 14% of the overall plasma lipid content, possibly due to the reported increase of Cer, LPC, PC and PE in MA CSF. Besides, a cumulative depletion of the plasma lipid asset was previously found in MA patients [<xref ref-type="bibr" rid="CR33">33</xref>]. Conversely, the current lipidomic analyses depicted an overall lipid enrichment for MA CSF. Plasma and CSF lipid pools could be deeply different, since the first one is more prone to change, whereas the blood-brain barrier (BBB) isolates the central nervous system microenvironment from the peripheral vasculature under homeostasis [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. The relation between lipid decrease at the systemic and local levels still need to be established. It is therefore crucial to gain further insights into the lipid metabolism in inflammatory BBB disruption and the involved mechanisms. Upon the occurrence of strokes, vessels undergo several adverse stimuli that enhance their permeability and instability. CSF may better reflect the pathological changes observed in vascular intimal hyperplasia of MA patients, due to its proximity with the stenotic arteries and the compensatory network of &#x0201c;moyamoya&#x0201d; vessels. Using a myelin-sensitive MR imaging technique, Hara and colleagues found that myelin damage and axonal damage may exist in MA patients [<xref ref-type="bibr" rid="CR59">59</xref>]. Accordingly, a BBB impairment was demonstrated in MA patients, mainly due to the typical fragile vascular system, to the Angiopoietin-2-related vascular plasticity and to endothelial dysfunction [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR73">73</xref>].</p><p id="Par78">We finally searched for simultaneously altered lipids in plasma and CSF. The discriminant analysis returned n&#x02009;=&#x02009;175 (plasma) and n&#x02009;=&#x02009;70 (CSF) lipids respectively, and n&#x02009;=&#x02009;10 lipids -belonging to the class of PC- resulted as commonly modulated species in plasma and CSF (Fig. <xref rid="Fig5" ref-type="fig">5</xref>A). The concentration of these lipid species was decreased in plasma and augmented in CSF (Fig. <xref rid="Fig5" ref-type="fig">5</xref>B), except for PC 42:7 that displayed an opposite trend. Thus, the previously reported lipid depletion in plasma was now counterbalanced by a CSF lipid enrichment. Such evidence seems to be of great relevance, as it was possible to identify PC as the unique class responsible for this peculiar finding. Our findings are in agreement with those previously reported by an untargeted metabolomic approach that identified a distinct LPC decrease in serum samples from MA patients, when compared to controls [<xref ref-type="bibr" rid="CR27">27</xref>].<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Common lipid features between plasma and CSF of MA. <bold>A</bold> Intersection size graph showing the number of lipids altered in both plasma [<xref ref-type="bibr" rid="CR33">33</xref>] and CSF of the same MA population. <bold>B</bold> Heatmap of lipids (n&#x02009;=&#x02009;10) altered in both plasma and CSF. The concentrations were auto-scaled and log-transformed for visualization. The color-scale for plasma samples differentiates values as high (yellow) and low (blue), whereas for CSF as high (pink) and low (green). HD, healthy donors; CTRL, controls subjects with unrelated cerebrovascular diseases. Statistical significance is evaluated by comparing ranks with Mann&#x02013;Whitney U test. <italic>P</italic> values are schematized as follows: **&#x02009;&#x0003c;&#x02009;0.01; ***&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="13023_2025_3782_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec15"><title>Limitations</title><p id="Par79">The main critical limitation of our study is the small sample size. Indeed, our pilot study focused only on a limited subset of MA patient&#x02019;s samples (Caucasian, females, mean age of 47 years, bilateral MA presentation) in whom it was possible to collect CSF, because they underwent neurosurgical revascularization procedures. However, such a selected panel precisely represented the whole MA population in Western countries, which is a relevant aspect considering the rarity of the disease. Accordingly, the control subjects were numerically limited because the large part of patients suffering cerebrovascular diseases do not require neurosurgical intervention allowing CSF sampling.</p><p id="Par80">In addition, we have collected data at only one time-point, after the neurological insult that determined this therapeutic option of utmost importance, thus the lack of longitudinal data prevented us from providing information on how lipid levels change over time. It is therefore rather premature to establish correlations between MA patient&#x02019;s lipidomic profiles and their clinical/demographical characteristics (e.g., disease severity, as assessed by neuroimaging and Suzuki grading), given the limited case history. However, since the disease affects many of our patients bilaterally, they will undergo a double neurosurgical operation months/years apart, and this will allow us to carry out this type of investigation in the future. Nevertheless, we are gradually completing an exhaustive and up-to-date clinical database, including information on disease follow-up that will be useful, in the next future, to correlate our results with the disease status/progression, with the final goal of building a framework to guide therapeutic and preventive approaches for MA management. Most certainly, the implications of our findings are worth considering to be extended to a more numerous cohort.</p></sec></sec><sec id="Sec16"><title>Conclusions</title><p id="Par81">There is an urgent need for translational research on circulating biomarkers for MA patients&#x02019; stratification, to drive personalized therapies and provide prognostic/progression advice to patients and relatives. Thus, the determination of the link between a specific measurable biomarker and significant clinical endpoints is mandatory. By capturing the intricate and multifaceted landscape of the lipidome and tracking changes in circulating lipid levels, lipidomics can depict distinct molecular phenotypes indicative of the physiological and pathological states of an organism [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR73">73</xref>&#x02013;<xref ref-type="bibr" rid="CR76">76</xref>]. Based on our knowledge, this study represents the first attempt to investigate the lipidome profile of CSF samples from a small subgroup of MA patients. Indeed, this study reveals that MA CSF lipid asset is homogeneous per se, but distinctly different from that of control subjects. Interestingly, the category of phospholipids showed a significant increase in MA CSF. Phospholipids are key players in cellular phenotyping, signaling, and homeostasis, maintaining a balance between structural integrity and dynamic responsiveness [<xref ref-type="bibr" rid="CR77">77</xref>]. Modified phospholipids can change the properties of membranes, and modulate cellular responses, or participate in signaling pathways regulating inflammation and immune response, recently suggested as second hits to trigger MA onset [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Specifically, PC emerged as the unique class implicated in the opposite trend between plasma and CSF of the same MA cohort. Thereby, abnormally high- (in CSF) and low- (in plasma) concentrations of this lipid class may play a critical role in MA onset and progression [<xref ref-type="bibr" rid="CR78">78</xref>] (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). Future efforts would be focused on validating these biomarkers using a larger sample size and a targeted lipidomic approach. We will extend the correlation betweeen a panel of selected circulating biomarkers (proteins and lipids) and disease outcome, with the final goal of building a framework to guide therapeutic and preventive approaches for MA management.<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>MA CSF lipidome profile analysis. The main deregulated lipid classes/species, associated with distinct pathological traits, are showed. Red arrows indicate the detection of increasing levels while the blue one stands for decreasing levels as compared to CSF of control subjects. CSF, cerebrospinal fluid; MA, moyamoya angiopathy (Figure created with BioRender)</p></caption><graphic xlink:href="13023_2025_3782_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13023_2025_3782_MOESM1_ESM.pdf"><caption><p>Supplementary Material 1. </p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACar</term><def><p id="Par5">Acylcarnitines</p></def></def-item><def-item><term>AUC</term><def><p id="Par6">Area under the curve</p></def></def-item><def-item><term>B</term><def><p id="Par7">Bilateral</p></def></def-item><def-item><term>BBB</term><def><p id="Par8">Blood-brain barrier</p></def></def-item><def-item><term>BHT</term><def><p id="Par9">Dibutylhydroxytoluene</p></def></def-item><def-item><term>CE</term><def><p id="Par10">Cholesterol esters</p></def></def-item><def-item><term>Cer</term><def><p id="Par11">Ceramides</p></def></def-item><def-item><term>chol</term><def><p id="Par12">Cholesterol</p></def></def-item><def-item><term>CHOL</term><def><p id="Par13">Total cholesterol</p></def></def-item><def-item><term>CI</term><def><p id="Par14">Confidence interval</p></def></def-item><def-item><term>CSF</term><def><p id="Par15">Cerebrospinal fluid</p></def></def-item><def-item><term>CTRL</term><def><p id="Par16">Controls</p></def></def-item><def-item><term>CVD</term><def><p id="Par17">Cerebrovascular disease</p></def></def-item><def-item><term>DAG</term><def><p id="Par18">Diacylglycerols</p></def></def-item><def-item><term>DHCer</term><def><p id="Par19">Dihydroceramides</p></def></def-item><def-item><term>ESO</term><def><p id="Par20">European stroke organisation</p></def></def-item><def-item><term>EtherPC</term><def><p id="Par21">Ether linked phosphatidylcholines</p></def></def-item><def-item><term>EtherPE</term><def><p id="Par22">Vinyl linked phosphatidylethanolamines</p></def></def-item><def-item><term>F</term><def><p id="Par23">Female</p></def></def-item><def-item><term>Gb3</term><def><p id="Par24">Globotriaosylceramide</p></def></def-item><def-item><term>GM3</term><def><p id="Par25">Gangliosides</p></def></def-item><def-item><term>HDL</term><def><p id="Par26">High-density lipoprotein</p></def></def-item><def-item><term>HexCer</term><def><p id="Par27">Hexosylceramides</p></def></def-item><def-item><term>LacCer</term><def><p id="Par28">Lactosylceramides</p></def></def-item><def-item><term>LDL</term><def><p id="Par29">Low-density lipoprotein</p></def></def-item><def-item><term>LPC</term><def><p id="Par30">Lysophosphatidylcholines</p></def></def-item><def-item><term>LPE</term><def><p id="Par31">Lysophosphatidylethanolamines</p></def></def-item><def-item><term>MA</term><def><p id="Par32">Moyamoya angiopathy</p></def></def-item><def-item><term>MAG</term><def><p id="Par33">Monoacylglycerols</p></def></def-item><def-item><term>MAGL</term><def><p id="Par34">MAG-lipase</p></def></def-item><def-item><term>MCA</term><def><p id="Par35">Middle cerebral artery</p></def></def-item><def-item><term>mRS</term><def><p id="Par36">Modified Rankin scale</p></def></def-item><def-item><term>N</term><def><p id="Par37">Number of subjects</p></def></def-item><def-item><term>na</term><def><p id="Par38">Not available</p></def></def-item><def-item><term>NIHSS</term><def><p id="Par39">National institutes of health stroke scale</p></def></def-item><def-item><term>ns</term><def><p id="Par40">Not significant</p></def></def-item><def-item><term>PC</term><def><p id="Par41">Phosphatidylcholines</p></def></def-item><def-item><term>PC1</term><def><p id="Par42">Principal component 1</p></def></def-item><def-item><term>PE</term><def><p id="Par43">Phosphatidylethanolamines</p></def></def-item><def-item><term>PI</term><def><p id="Par44">Phosphatidylinositoles</p></def></def-item><def-item><term>PLS-DA</term><def><p id="Par45">Partial least squares discriminant analysis</p></def></def-item><def-item><term>RNF213</term><def><p id="Par46">Ring finger protein 213</p></def></def-item><def-item><term>ROC</term><def><p id="Par47">Receiver operating characteristic</p></def></def-item><def-item><term>SM</term><def><p id="Par48">Sphingomyelins</p></def></def-item><def-item><term>STA</term><def><p id="Par49">Superficial temporal artery</p></def></def-item><def-item><term>SULF</term><def><p id="Par50">Sulfatides</p></def></def-item><def-item><term>TAG</term><def><p id="Par51">Triacylglycerols</p></def></def-item><def-item><term>TG</term><def><p id="Par52">Triglycerides</p></def></def-item><def-item><term>TIA</term><def><p id="Par53">Transient ischemic attack</p></def></def-item><def-item><term>U</term><def><p id="Par54">Unilateral</p></def></def-item><def-item><term>VIP</term><def><p id="Par55">Variance importance in projection</p></def></def-item><def-item><term>y</term><def><p id="Par56">Years</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Co-first authors: Antonella Potenza and Gemma Gorla.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>AP: data curation, methodology, formal analysis, writing&#x02014;original draft. GG: data curation, methodology, formal analysis, writing&#x02014;original draft. TC: data curation, methodology, formal analysis, writing&#x02014;review and editing. GP: data curation, methodology, formal analysis, writing&#x02014;review and editing. MDC: data curation, methodology, formal analysis, software. FA: formal analysis, investigation. IGV: formal analysis, investigation. PF: resources, investigation. IC: formal analysis, investigation, methodology. RP: resources, supervision, writing&#x02014;review and editing. NR: formal analysis, investigation, methodology. AB: funding acquisition, supervision, writing&#x02014;review and editing. LG: conceptualization, funding acquisition, supervision, writing&#x02014;review and editing.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was partially supported by the Italian Ministry of Health (grant number RRC 2018&#x02013;2025 to L.G.; grant number RF-2019-12369247 to A.B; grant number RCR-2021-23671214 to A.B.). We express our appreciation to the Italian Ministry of Health and to the European Union&#x02014;Next Generation EU&#x02014;NRRP M6C2&#x02014;Investment 2.1 Enhancement and strengthening of biomedical research in the NHS, that supported this study (grant number PNRR-MR1-2022-12376618 to A.B).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The study raw data supporting lipidomic reported results can be found in the MetaboLights public repository (Study-ID MTBLS9744; <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/metabolights/editor/www.ebi.ac.uk/metabolights/MTBLS9744">https://www.ebi.ac.uk/metabolights/editor/www.ebi.ac.uk/metabolights/MTBLS9744</ext-link>).</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par82">The study design was approved by the Ethics Committee of the Fondazione IRCCS Istituto Neurologico &#x0201c;C. Besta&#x0201d; of Milan (GEN-O-MA clinical study, report no. 12, 10/01/2014). Informed written consent for study participation and sample collection from all patients and controls were mandatory for study inclusion.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par83">Written informed consent was obtained from the individuals for the publication of any potentially identifiable images or data included in this article. Privacy procedures were applied to protect patients&#x02019; and control subjects&#x02019; personal identities.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par84">Not applicable.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Ya</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Progress in moyamoya disease</article-title><source>Neurosurg Rev</source><year>2020</year><volume>43</volume><issue>2</issue><fpage>371</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1007/s10143-018-0994-5</pub-id><pub-id pub-id-type="pmid">29911252</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Shang S, Zhou D, Ya J, Li S, Yang Q, Ding Y, et al. Progress in moyamoya disease. Neurosurg Rev. 2020;43(2):371&#x02013;82. 10.1007/s10143-018-0994-5.<pub-id pub-id-type="pmid">29911252</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Guey</surname><given-names>S</given-names></name><name><surname>Tournier-Lasserve</surname><given-names>E</given-names></name><name><surname>Herv&#x000e9;</surname><given-names>D</given-names></name><name><surname>Kossorotoff</surname><given-names>M</given-names></name></person-group><article-title>Moyamoya disease and syndromes: from genetics to clinical management</article-title><source>Appl Clin Genet</source><year>2015</year><volume>16</volume><issue>8</issue><fpage>49</fpage><lpage>68</lpage></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Guey S, Tournier-Lasserve E, Herv&#x000e9; D, Kossorotoff M. Moyamoya disease and syndromes: from genetics to clinical management. Appl Clin Genet. 2015;16(8):49&#x02013;68.</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>E</given-names></name><name><surname>Saeki</surname><given-names>N</given-names></name><name><surname>Oishi</surname><given-names>H</given-names></name><name><surname>Hirai</surname><given-names>S</given-names></name><name><surname>Yamaura</surname><given-names>A</given-names></name></person-group><article-title>Long-term natural history of hemorrhagic moyamoya disease in 42 patients</article-title><source>J Neurosurg</source><year>2000</year><volume>93</volume><issue>6</issue><fpage>976</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.3171/jns.2000.93.6.0976</pub-id><pub-id pub-id-type="pmid">11117870</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Kobayashi E, Saeki N, Oishi H, Hirai S, Yamaura A. Long-term natural history of hemorrhagic moyamoya disease in 42 patients. J Neurosurg. 2000;93(6):976&#x02013;80. 10.3171/jns.2000.93.6.0976.<pub-id pub-id-type="pmid">11117870</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Mejia-Munne</surname><given-names>JC</given-names></name><name><surname>Ellis</surname><given-names>JA</given-names></name><name><surname>Feldstein</surname><given-names>NA</given-names></name><name><surname>Meyers</surname><given-names>PM</given-names></name><name><surname>Connolly</surname><given-names>ES</given-names></name></person-group><article-title>Moyamoya and inflammation</article-title><source>World Neurosurg.</source><year>2017</year><volume>100</volume><fpage>575</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1016/j.wneu.2017.01.012</pub-id><pub-id pub-id-type="pmid">28093343</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Mejia-Munne JC, Ellis JA, Feldstein NA, Meyers PM, Connolly ES. Moyamoya and inflammation. World Neurosurg. 2017;100:575&#x02013;8. 10.1016/j.wneu.2017.01.012.<pub-id pub-id-type="pmid">28093343</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Mikami</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Komatsu</surname><given-names>K</given-names></name><name><surname>Mikuni</surname><given-names>N</given-names></name></person-group><article-title>Influence of inflammatory disease on the pathophysiology of moyamoya disease and quasi-moyamoya disease</article-title><source>Neurol Med Chir (Tokyo)</source><year>2019</year><volume>59</volume><issue>10</issue><fpage>361</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.2176/nmc.ra.2019-0059</pub-id><pub-id pub-id-type="pmid">31281171</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Mikami T, Suzuki H, Komatsu K, Mikuni N. Influence of inflammatory disease on the pathophysiology of moyamoya disease and quasi-moyamoya disease. Neurol Med Chir (Tokyo). 2019;59(10):361&#x02013;70. 10.2176/nmc.ra.2019-0059.<pub-id pub-id-type="pmid">31281171</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Dorschel</surname><given-names>KB</given-names></name><name><surname>Wanebo</surname><given-names>JE</given-names></name></person-group><article-title>Physiological and pathophysiological mechanisms of the molecular and cellular biology of angiogenesis and inflammation in moyamoya angiopathy and related vascular diseases</article-title><source>Front Neurol</source><year>2023</year><volume>16</volume><issue>14</issue><fpage>661611</fpage><pub-id pub-id-type="doi">10.3389/fneur.2023.661611</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Dorschel KB, Wanebo JE. Physiological and pathophysiological mechanisms of the molecular and cellular biology of angiogenesis and inflammation in moyamoya angiopathy and related vascular diseases. Front Neurol. 2023;16(14):661611. 10.3389/fneur.2023.661611.</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Bauman</surname><given-names>MMJ</given-names></name><name><surname>Seas</surname><given-names>A</given-names></name><name><surname>Harrison</surname><given-names>DJ</given-names></name><name><surname>Pennington</surname><given-names>Z</given-names></name><name><surname>Brown</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Association of moyamoya vasculopathy with autoimmune disease: a systematic review and pooled analysis</article-title><source>Neurosurg Rev</source><year>2023</year><volume>46</volume><issue>1</issue><fpage>220</fpage><pub-id pub-id-type="doi">10.1007/s10143-023-02123-z</pub-id><pub-id pub-id-type="pmid">37658996</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Singh R, Bauman MMJ, Seas A, Harrison DJ, Pennington Z, Brown NJ, et al. Association of moyamoya vasculopathy with autoimmune disease: a systematic review and pooled analysis. Neurosurg Rev. 2023;46(1):220. 10.1007/s10143-023-02123-z.<pub-id pub-id-type="pmid">37658996</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Asselman</surname><given-names>C</given-names></name><name><surname>Hemelsoet</surname><given-names>D</given-names></name><name><surname>Eggermont</surname><given-names>D</given-names></name><name><surname>Dermaut</surname><given-names>B</given-names></name><name><surname>Impens</surname><given-names>F</given-names></name></person-group><article-title>Moyamoya disease emerging as an immune-related angiopathy</article-title><source>Trends Mol Med</source><year>2022</year><volume>28</volume><issue>11</issue><fpage>939</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2022.08.009</pub-id><pub-id pub-id-type="pmid">36115805</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Asselman C, Hemelsoet D, Eggermont D, Dermaut B, Impens F. Moyamoya disease emerging as an immune-related angiopathy. Trends Mol Med. 2022;28(11):939&#x02013;50. 10.1016/j.molmed.2022.08.009.<pub-id pub-id-type="pmid">36115805</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Sigdel</surname><given-names>TK</given-names></name><name><surname>Shoemaker</surname><given-names>LD</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Butte</surname><given-names>AJ</given-names></name><name><surname>Sarwal</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Immune response profiling identifies autoantibodies specific to moyamoya patients</article-title><source>Orphanet J Rare Dis</source><year>2013</year><volume>8</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/1750-1172-8-45</pub-id><pub-id pub-id-type="pmid">23518061</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Sigdel TK, Shoemaker LD, Chen R, Li L, Butte AJ, Sarwal MM, et al. Immune response profiling identifies autoantibodies specific to moyamoya patients. Orphanet J Rare Dis. 2013;8:45. 10.1186/1750-1172-8-45.<pub-id pub-id-type="pmid">23518061</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>JD</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>AC</given-names></name><name><surname>Ho</surname><given-names>E</given-names></name><name><surname>Nagesh</surname><given-names>D</given-names></name><name><surname>Khoshnood</surname><given-names>M</given-names></name><etal/></person-group><article-title>Increased autoimmunity in individuals with down syndrome and moyamoya disease</article-title><source>Front Neurol</source><year>2021</year><volume>8</volume><issue>12</issue><fpage>724969</fpage><pub-id pub-id-type="doi">10.3389/fneur.2021.724969</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Santoro JD, Lee S, Wang AC, Ho E, Nagesh D, Khoshnood M, et al. Increased autoimmunity in individuals with down syndrome and moyamoya disease. Front Neurol. 2021;8(12):724969. 10.3389/fneur.2021.724969.</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Lanterna</surname><given-names>LA</given-names></name><name><surname>Galliani</surname><given-names>S</given-names></name><name><surname>Zangari</surname><given-names>R</given-names></name><name><surname>Conti</surname><given-names>L</given-names></name><name><surname>Brembilla</surname><given-names>C</given-names></name><name><surname>Gritti</surname><given-names>P</given-names></name><etal/></person-group><article-title>Thyroid autoantibodies and the clinical presentation of moyamoya disease: a prospective study</article-title><source>J Stroke Cerebrovasc Dis</source><year>2018</year><volume>27</volume><fpage>1194</fpage><lpage>1199</lpage><pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2017.11.037</pub-id><pub-id pub-id-type="pmid">29305275</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Lanterna LA, Galliani S, Zangari R, Conti L, Brembilla C, Gritti P, et al. Thyroid autoantibodies and the clinical presentation of moyamoya disease: a prospective study. J Stroke Cerebrovasc Dis. 2018;27:1194&#x02013;9. 10.1016/j.jstrokecerebrovasdis.2017.11.037.<pub-id pub-id-type="pmid">29305275</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Sum</surname><given-names>CH</given-names></name><name><surname>Tsang</surname><given-names>ACO</given-names></name><name><surname>Cheng</surname><given-names>KK</given-names></name><name><surname>Ho</surname><given-names>WW</given-names></name><name><surname>Leung</surname><given-names>GKK</given-names></name><name><surname>Lui</surname><given-names>WM</given-names></name></person-group><article-title>Surgical revascularization for moyamoya angiopathy: clinical and radiological outcomes of direct and indirect bypasses in 86 affected hemispheres</article-title><source>J Clin Neurosci</source><year>2022</year><volume>99</volume><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.jocn.2022.02.036</pub-id><pub-id pub-id-type="pmid">35255359</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Sum CH, Tsang ACO, Cheng KK, Ho WW, Leung GKK, Lui WM. Surgical revascularization for moyamoya angiopathy: clinical and radiological outcomes of direct and indirect bypasses in 86 affected hemispheres. J Clin Neurosci. 2022;99:66&#x02013;72. 10.1016/j.jocn.2022.02.036.<pub-id pub-id-type="pmid">35255359</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>AM</given-names></name><name><surname>Karri</surname><given-names>SK</given-names></name><name><surname>Ogilvy</surname><given-names>CS</given-names></name><name><surname>Zhao</surname><given-names>N</given-names></name></person-group><article-title>Is there a role for treating inflammation in moyamoya disease? A review of histopathology, genetics, and signaling cascades</article-title><source>Front Neurol</source><year>2013</year><volume>14</volume><issue>4</issue><fpage>105</fpage></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Young AM, Karri SK, Ogilvy CS, Zhao N. Is there a role for treating inflammation in moyamoya disease? A review of histopathology, genetics, and signaling cascades. Front Neurol. 2013;14(4):105.</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Guey</surname><given-names>S</given-names></name><name><surname>Kraemer</surname><given-names>M</given-names></name><name><surname>Herv&#x000e9;</surname><given-names>D</given-names></name><name><surname>Ludwig</surname><given-names>T</given-names></name><name><surname>Kossorotoff</surname><given-names>M</given-names></name><name><surname>Bergametti</surname><given-names>F</given-names></name><etal/></person-group><article-title>FREX consortium. Rare RNF213 variants in the C-terminal region encompassing the RING-finger domain are associated with moyamoya angiopathy in Caucasians</article-title><source>Eur J Hum Genet</source><year>2017</year><volume>25</volume><issue>8</issue><fpage>995</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2017.92</pub-id><pub-id pub-id-type="pmid">28635953</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Guey S, Kraemer M, Herv&#x000e9; D, Ludwig T, Kossorotoff M, Bergametti F, et al. FREX consortium. Rare RNF213 variants in the C-terminal region encompassing the RING-finger domain are associated with moyamoya angiopathy in Caucasians. Eur J Hum Genet. 2017;25(8):995&#x02013;1003. 10.1038/ejhg.2017.92.<pub-id pub-id-type="pmid">28635953</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name></person-group><article-title>Epidemiology, diagnosis and treatment of moyamoya disease</article-title><source>Exp Ther Med</source><year>2019</year><volume>17</volume><issue>3</issue><fpage>1977</fpage><lpage>1984</lpage><pub-id pub-id-type="doi">10.3892/etm.2019.7198</pub-id><pub-id pub-id-type="pmid">30867689</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zhang H, Zheng L, Feng L. Epidemiology, diagnosis and treatment of moyamoya disease. Exp Ther Med. 2019;17(3):1977&#x02013;84. 10.3892/etm.2019.7198.<pub-id pub-id-type="pmid">30867689</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>T</given-names></name><name><surname>Houkin</surname><given-names>K</given-names></name><name><surname>Kuroda</surname><given-names>S</given-names></name></person-group><article-title>Novel epidemiological features of moyamoya disease</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2008</year><volume>79</volume><issue>8</issue><fpage>900</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2007.130666</pub-id><pub-id pub-id-type="pmid">18077479</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry. 2008;79(8):900&#x02013;4. 10.1136/jnnp.2007.130666.<pub-id pub-id-type="pmid">18077479</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Kamada</surname><given-names>F</given-names></name><name><surname>Aoki</surname><given-names>Y</given-names></name><name><surname>Narisawa</surname><given-names>A</given-names></name><name><surname>Abe</surname><given-names>Y</given-names></name><name><surname>Komatsuzaki</surname><given-names>S</given-names></name><name><surname>Kikuchi</surname><given-names>A</given-names></name><etal/></person-group><article-title>A genome-wide association study identifies RNF213 as the first moyamoya disease gene</article-title><source>J Hum Genet</source><year>2011</year><volume>56</volume><issue>1</issue><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/jhg.2010.132</pub-id><pub-id pub-id-type="pmid">21048783</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. A genome-wide association study identifies RNF213 as the first moyamoya disease gene. J Hum Genet. 2011;56(1):34&#x02013;40. 10.1038/jhg.2010.132.<pub-id pub-id-type="pmid">21048783</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Experimental animal models for moyamoya disease: a species-oriented scoping review</article-title><source>Front Surg</source><year>2022</year><volume>1</volume><issue>9</issue><fpage>929871</fpage><pub-id pub-id-type="doi">10.3389/fsurg.2022.929871</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Cao L, Dong Y, Sun K, Li D, Wang H, Li H, et al. Experimental animal models for moyamoya disease: a species-oriented scoping review. Front Surg. 2022;1(9):929871. 10.3389/fsurg.2022.929871.</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Correia</surname><given-names>M</given-names></name><name><surname>Silva</surname><given-names>I</given-names></name><name><surname>Gabriel</surname><given-names>D</given-names></name><name><surname>Simr&#x000e9;n</surname><given-names>J</given-names></name><name><surname>Carneiro</surname><given-names>A</given-names></name><name><surname>Ribeiro</surname><given-names>S</given-names></name><etal/></person-group><article-title>Early plasma biomarker dynamic profiles are associated with acute ischemic stroke outcomes</article-title><source>Eur J Neurol</source><year>2022</year><volume>29</volume><issue>6</issue><fpage>1630</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1111/ene.15273</pub-id><pub-id pub-id-type="pmid">35124870</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Correia M, Silva I, Gabriel D, Simr&#x000e9;n J, Carneiro A, Ribeiro S, et al. Early plasma biomarker dynamic profiles are associated with acute ischemic stroke outcomes. Eur J Neurol. 2022;29(6):1630&#x02013;42. 10.1111/ene.15273.<pub-id pub-id-type="pmid">35124870</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Micha&#x000eb;lsson</surname><given-names>I</given-names></name><name><surname>Hall&#x000e9;n</surname><given-names>T</given-names></name><name><surname>Carstam</surname><given-names>L</given-names></name><name><surname>Laesser</surname><given-names>M</given-names></name><name><surname>Bj&#x000f6;rkman-Burtscher</surname><given-names>IM</given-names></name><name><surname>S&#x000f6;rbo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Circulating brain injury biomarkers: a novel method for quantification of the impact on the brain after tumor surgery</article-title><source>Neurosurgery</source><year>2023</year><volume>93</volume><issue>4</issue><fpage>847</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1227/neu.0000000000002510</pub-id><pub-id pub-id-type="pmid">37140203</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Micha&#x000eb;lsson I, Hall&#x000e9;n T, Carstam L, Laesser M, Bj&#x000f6;rkman-Burtscher IM, S&#x000f6;rbo A, et al. Circulating brain injury biomarkers: a novel method for quantification of the impact on the brain after tumor surgery. Neurosurgery. 2023;93(4):847&#x02013;56. 10.1227/neu.0000000000002510.<pub-id pub-id-type="pmid">37140203</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Yue</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Mao</surname><given-names>C</given-names></name></person-group><article-title>Target-triggered formation of artificial enzymes on filamentous phage for ultrasensitive direct detection of circulating mirna biomarkers in clinical samples</article-title><source>Angew Chem Int Ed Engl</source><year>2022</year><volume>61</volume><issue>45</issue><fpage>e202210121</fpage><pub-id pub-id-type="doi">10.1002/anie.202210121</pub-id><pub-id pub-id-type="pmid">36108201</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Zeng Y, Yue H, Cao B, Li Y, Yang M, Mao C. Target-triggered formation of artificial enzymes on filamentous phage for ultrasensitive direct detection of circulating mirna biomarkers in clinical samples. Angew Chem Int Ed Engl. 2022;61(45):e202210121. 10.1002/anie.202210121.<pub-id pub-id-type="pmid">36108201</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Gatti</surname><given-names>L</given-names></name><name><surname>Bersano</surname><given-names>A</given-names></name><name><surname>Gorla</surname><given-names>G</given-names></name><name><surname>Pollaci</surname><given-names>G</given-names></name><name><surname>Carrozzini</surname><given-names>T</given-names></name><name><surname>Potenza</surname><given-names>A</given-names></name></person-group><article-title>Multi-omic approaches for biomarker discovery in moyamoya disease</article-title><source>Ann Clin Transl Neurol</source><year>2024</year><volume>4</volume><issue>2</issue><fpage>e270</fpage><pub-id pub-id-type="doi">10.1002/ctd2.270</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Gatti L, Bersano A, Gorla G, Pollaci G, Carrozzini T, Potenza A. Multi-omic approaches for biomarker discovery in moyamoya disease. Ann Clin Transl Neurol. 2024;4(2):e270. 10.1002/ctd2.270.</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Carrozzini</surname><given-names>T</given-names></name><name><surname>Pollaci</surname><given-names>G</given-names></name><name><surname>Gorla</surname><given-names>G</given-names></name><name><surname>Potenza</surname><given-names>A</given-names></name><name><surname>Rifino</surname><given-names>N</given-names></name><name><surname>Acerbi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Proteome profiling of the dura mater in patients with moyamoya angiopathy</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>13</issue><fpage>11194</fpage><pub-id pub-id-type="doi">10.3390/ijms241311194</pub-id><pub-id pub-id-type="pmid">37446373</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Carrozzini T, Pollaci G, Gorla G, Potenza A, Rifino N, Acerbi F, et al. Proteome profiling of the dura mater in patients with moyamoya angiopathy. Int J Mol Sci. 2023;24(13):11194. 10.3390/ijms241311194.<pub-id pub-id-type="pmid">37446373</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Ji</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><article-title>Data-independent acquisition-based serum proteomic profiling of adult moyamoya disease patients reveals the potential pathogenesis of vascular changes</article-title><source>J Mol Neurosci</source><year>2022</year><volume>72</volume><issue>12</issue><fpage>2473</fpage><lpage>2485</lpage><pub-id pub-id-type="doi">10.1007/s12031-022-02092-w</pub-id><pub-id pub-id-type="pmid">36520382</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Wang Z, Ji C, Han Q, Wang Z, Huang Y. Data-independent acquisition-based serum proteomic profiling of adult moyamoya disease patients reveals the potential pathogenesis of vascular changes. J Mol Neurosci. 2022;72(12):2473&#x02013;85. 10.1007/s12031-022-02092-w.<pub-id pub-id-type="pmid">36520382</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>W</given-names></name><name><surname>Duan</surname><given-names>L</given-names></name></person-group><article-title>Proteomic profiling of exosomes from hemorrhagic moyamoya disease and dysfunction of mitochondria in endothelial cells</article-title><source>Stroke</source><year>2021</year><volume>52</volume><issue>10</issue><fpage>3351</fpage><lpage>3361</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.120.032297</pub-id><pub-id pub-id-type="pmid">34334053</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Wang X, Han C, Jia Y, Wang J, Ge W, Duan L. Proteomic profiling of exosomes from hemorrhagic moyamoya disease and dysfunction of mitochondria in endothelial cells. Stroke. 2021;52(10):3351&#x02013;61. 10.1161/STROKEAHA.120.032297.<pub-id pub-id-type="pmid">34334053</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>Liquid chromatography coupled to mass spectrometry metabolomic analysis of cerebrospinal fluid revealed the metabolic characteristics of moyamoya disease</article-title><source>Front Neurol</source><year>2024</year><volume>15</volume><issue>15</issue><fpage>1298385</fpage><pub-id pub-id-type="doi">10.3389/fneur.2024.1298385</pub-id><pub-id pub-id-type="pmid">38426176</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Yu J, Chen T, Li X, Chen J, Wei W, Zhang J. Liquid chromatography coupled to mass spectrometry metabolomic analysis of cerebrospinal fluid revealed the metabolic characteristics of moyamoya disease. Front Neurol. 2024;15(15):1298385. 10.3389/fneur.2024.1298385.<pub-id pub-id-type="pmid">38426176</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Hao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Metabolomic signatures associated with pathological angiogenesis in moyamoya disease</article-title><source>Clin Transl Med</source><year>2023</year><volume>13</volume><issue>12</issue><fpage>e1492</fpage><pub-id pub-id-type="doi">10.1002/ctm2.1492</pub-id><pub-id pub-id-type="pmid">38037492</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">He S, Wang Y, Liu Z, Zhang J, Hao X, Wang X, et al. Metabolomic signatures associated with pathological angiogenesis in moyamoya disease. Clin Transl Med. 2023;13(12):e1492. 10.1002/ctm2.1492.<pub-id pub-id-type="pmid">38037492</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Pollaci</surname><given-names>G</given-names></name><name><surname>Gorla</surname><given-names>G</given-names></name><name><surname>Potenza</surname><given-names>A</given-names></name><name><surname>Carrozzini</surname><given-names>T</given-names></name><name><surname>Canavero</surname><given-names>I</given-names></name><name><surname>Bersano</surname><given-names>A</given-names></name><etal/></person-group><article-title>Novel multifaceted roles for RNF213 protein</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>9</issue><fpage>4492</fpage><pub-id pub-id-type="doi">10.3390/ijms23094492</pub-id><pub-id pub-id-type="pmid">35562882</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Pollaci G, Gorla G, Potenza A, Carrozzini T, Canavero I, Bersano A, et al. Novel multifaceted roles for RNF213 protein. Int J Mol Sci. 2022;23(9):4492. 10.3390/ijms23094492.<pub-id pub-id-type="pmid">35562882</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Fantini</surname><given-names>J</given-names></name><name><surname>Barrantes</surname><given-names>FJ</given-names></name></person-group><article-title>Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function</article-title><source>Biochim Biophys Acta</source><year>2009</year><volume>1788</volume><issue>11</issue><fpage>2345</fpage><lpage>2361</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2009.08.016</pub-id><pub-id pub-id-type="pmid">19733149</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Fantini J, Barrantes FJ. Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function. Biochim Biophys Acta. 2009;1788(11):2345&#x02013;61. 10.1016/j.bbamem.2009.08.016.<pub-id pub-id-type="pmid">19733149</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name></person-group><article-title>Cholesterol metabolism and homeostasis in the brain</article-title><source>Protein Cell</source><year>2015</year><volume>6</volume><issue>4</issue><fpage>254</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1007/s13238-014-0131-3</pub-id><pub-id pub-id-type="pmid">25682154</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell. 2015;6(4):254&#x02013;64. 10.1007/s13238-014-0131-3.<pub-id pub-id-type="pmid">25682154</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Tong</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>X</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>In-depth cerebrovascular lipidomics profiling for discovering novel biomarkers and mechanisms in moyamoya and intracranial atherosclerotic disease</article-title><source>Int J Surg</source><year>2024</year><volume>111</volume><issue>1</issue><fpage>1607</fpage><lpage>1613</lpage><pub-id pub-id-type="doi">10.1097/JS9.0000000000002092</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">He K, Wang X, Gu Y, Tong X, Qin X, Liao Y, et al. In-depth cerebrovascular lipidomics profiling for discovering novel biomarkers and mechanisms in moyamoya and intracranial atherosclerotic disease. Int J Surg. 2024;111(1):1607&#x02013;13. 10.1097/JS9.0000000000002092.</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Gorla</surname><given-names>G</given-names></name><name><surname>Potenza</surname><given-names>A</given-names></name><name><surname>Carrozzini</surname><given-names>T</given-names></name><name><surname>Pollaci</surname><given-names>G</given-names></name><name><surname>Acerbi</surname><given-names>F</given-names></name><name><surname>Vetrano</surname><given-names>IG</given-names></name><etal/></person-group><article-title>Angiopoietin-2 associates with poor prognosis in moyamoya angiopathy</article-title><source>Ann Clin Transl Neurol</source><year>2024</year><volume>11</volume><issue>6</issue><fpage>1590</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.1002/acn3.52076</pub-id><pub-id pub-id-type="pmid">38655722</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Gorla G, Potenza A, Carrozzini T, Pollaci G, Acerbi F, Vetrano IG, et al. Angiopoietin-2 associates with poor prognosis in moyamoya angiopathy. Ann Clin Transl Neurol. 2024;11(6):1590&#x02013;603. 10.1002/acn3.52076.<pub-id pub-id-type="pmid">38655722</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Dei Cas</surname><given-names>M</given-names></name><name><surname>Carrozzini</surname><given-names>T</given-names></name><name><surname>Pollaci</surname><given-names>G</given-names></name><name><surname>Potenza</surname><given-names>A</given-names></name><name><surname>Nava</surname><given-names>S</given-names></name><name><surname>Canavero</surname><given-names>I</given-names></name><etal/></person-group><article-title>Plasma lipid profiling contributes to untangle the complexity of moyamoya arteriopathy</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><issue>24</issue><fpage>13410</fpage><pub-id pub-id-type="doi">10.3390/ijms222413410</pub-id><pub-id pub-id-type="pmid">34948203</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Dei Cas M, Carrozzini T, Pollaci G, Potenza A, Nava S, Canavero I, et al. Plasma lipid profiling contributes to untangle the complexity of moyamoya arteriopathy. Int J Mol Sci. 2021;22(24):13410. 10.3390/ijms222413410.<pub-id pub-id-type="pmid">34948203</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis; Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo). 2012;52(5):245&#x02013;66. 10.2176/nmc.52.245</mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Bersano A, Bedini G, Nava S, Acerbi F, Sebastiano DR, Binelli S, et al.; GEN-O-MA study group. GEN-O-MA project: an Italian network studying clinical course and pathogenic pathways of moyamoya disease-study protocol and preliminary results. Neurol Sci. 2019;40(3):561&#x02013;570. 10.1007/s10072-018-3664-z.</mixed-citation></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Bersano</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Fuentes</surname><given-names>B</given-names></name><name><surname>Acerbi</surname><given-names>F</given-names></name><name><surname>Canavero</surname><given-names>I</given-names></name><name><surname>Tournier-Lasserve</surname><given-names>E</given-names></name><etal/></person-group><article-title>European stroke organisation (ESO) guidelines on moyamoya angiopathy endorsed by vascular European reference network (VASCERN)</article-title><source>Eur Stroke J</source><year>2023</year><volume>8</volume><issue>1</issue><fpage>55</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1177/23969873221144089</pub-id><pub-id pub-id-type="pmid">37021176</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Bersano A, Khan N, Fuentes B, Acerbi F, Canavero I, Tournier-Lasserve E, et al. European stroke organisation (ESO) guidelines on moyamoya angiopathy endorsed by vascular European reference network (VASCERN). Eur Stroke J. 2023;8(1):55&#x02013;84. 10.1177/23969873221144089.<pub-id pub-id-type="pmid">37021176</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>J</given-names></name><name><surname>Takaku</surname><given-names>A</given-names></name></person-group><article-title>Cerebrovascular, &#x0201c;moyamoya&#x0201d; disease. Disease showing abnormal net-like vessels in base of brain</article-title><source>Arch Neurol</source><year>1969</year><volume>20</volume><issue>3</issue><fpage>288</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1001/archneur.1969.00480090076012</pub-id><pub-id pub-id-type="pmid">5775283</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Suzuki J, Takaku A. Cerebrovascular, &#x0201c;moyamoya&#x0201d; disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20(3):288&#x02013;99. 10.1001/archneur.1969.00480090076012.<pub-id pub-id-type="pmid">5775283</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">MS-DIAL ver. 4.0. RIKEN Center for Sustainable Resource Science, Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa, Japan. <ext-link ext-link-type="uri" xlink:href="http://prime.psc.riken.jp/compms">http://prime.psc.riken.jp/compms</ext-link> /msdial/main.html. Accessed 29 Dec 2023.</mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">MetaboLights Database. EMBL-EBI, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK. <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/metabolights/editor/study/MTBLS9744/descriptors">https://www.ebi.ac.uk/metabolights/editor/study/MTBLS9744/descriptors</ext-link>. Accessed 15 May 2024</mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">MetaboAnalyst ver. 5.0. McGill Data Center and Compute Canada, Montr&#x000e9;al, Canada. <ext-link ext-link-type="uri" xlink:href="https://www.metaboanalyst.ca">https://www.metaboanalyst.ca</ext-link>. Accessed 17 Dec 2023</mixed-citation></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Tinelli</surname><given-names>F</given-names></name><name><surname>Nava</surname><given-names>S</given-names></name><name><surname>Arioli</surname><given-names>F</given-names></name><name><surname>Bedini</surname><given-names>G</given-names></name><name><surname>Scelzo</surname><given-names>E</given-names></name><name><surname>Lisini</surname><given-names>D</given-names></name><etal/></person-group><article-title>Vascular remodeling in moyamoya angiopathy: from peripheral blood mononuclear cells to endothelial cells</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><issue>16</issue><fpage>5763</fpage><pub-id pub-id-type="doi">10.3390/ijms21165763</pub-id><pub-id pub-id-type="pmid">32796702</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Tinelli F, Nava S, Arioli F, Bedini G, Scelzo E, Lisini D, et al. Vascular remodeling in moyamoya angiopathy: from peripheral blood mononuclear cells to endothelial cells. Int J Mol Sci. 2020;21(16):5763. 10.3390/ijms21165763.<pub-id pub-id-type="pmid">32796702</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Canavero</surname><given-names>I</given-names></name><name><surname>Vetrano</surname><given-names>IG</given-names></name><name><surname>Zedde</surname><given-names>M</given-names></name><name><surname>Pascarella</surname><given-names>R</given-names></name><name><surname>Acerbi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Clinical management of moyamoya patients</article-title><source>J Clin Med</source><year>2021</year><volume>10</volume><issue>16</issue><fpage>3628</fpage><pub-id pub-id-type="doi">10.3390/jcm10163628</pub-id><pub-id pub-id-type="pmid">34441923</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Canavero I, Vetrano IG, Zedde M, Pascarella R, Acerbi F, et al. Clinical management of moyamoya patients. J Clin Med. 2021;10(16):3628. 10.3390/jcm10163628.<pub-id pub-id-type="pmid">34441923</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name></person-group><article-title>Ceramide in cerebrovascular diseases</article-title><source>Front Cell Neurosci</source><year>2023</year><volume>2</volume><issue>17</issue><fpage>1191609</fpage><pub-id pub-id-type="doi">10.3389/fncel.2023.1191609</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Yuan H, Zhu B, Li C, Zhao Z. Ceramide in cerebrovascular diseases. Front Cell Neurosci. 2023;2(17):1191609. 10.3389/fncel.2023.1191609.</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Adibhatla</surname><given-names>RM</given-names></name><name><surname>Hatcher</surname><given-names>JF</given-names></name></person-group><article-title>Cytidine 5&#x02019;-diphosphocholine (CDP-choline) in stroke and other CNS disorders</article-title><source>Neurochem Res</source><year>2005</year><volume>30</volume><issue>1</issue><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s11064-004-9681-8</pub-id><pub-id pub-id-type="pmid">15756928</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Adibhatla RM, Hatcher JF. Cytidine 5&#x02019;-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochem Res. 2005;30(1):15&#x02013;23. 10.1007/s11064-004-9681-8.<pub-id pub-id-type="pmid">15756928</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Magaquian</surname><given-names>D</given-names></name><name><surname>Delgado Oca&#x000f1;a</surname><given-names>S</given-names></name><name><surname>Perez</surname><given-names>C</given-names></name><name><surname>Banchio</surname><given-names>C</given-names></name></person-group><article-title>Phosphatidylcholine restores neuronal plasticity of neural stem cells under inflammatory stress</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>22891</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-02361-5</pub-id><pub-id pub-id-type="pmid">34819604</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Magaquian D, Delgado Oca&#x000f1;a S, Perez C, Banchio C. Phosphatidylcholine restores neuronal plasticity of neural stem cells under inflammatory stress. Sci Rep. 2021;11(1):22891. 10.1038/s41598-021-02361-5.<pub-id pub-id-type="pmid">34819604</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Blondeau</surname><given-names>N</given-names></name><name><surname>Lauritzen</surname><given-names>I</given-names></name><name><surname>Widmann</surname><given-names>C</given-names></name><name><surname>Lazdunski</surname><given-names>M</given-names></name><name><surname>Heurteaux</surname><given-names>C</given-names></name></person-group><article-title>A potent protective role of lysophospholipids against global cerebral ischemia and glutamate excitotoxicity in neuronal cultures</article-title><source>J Cereb Blood Flow Metab</source><year>2002</year><volume>22</volume><issue>7</issue><fpage>821</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1097/00004647-200207000-00007</pub-id><pub-id pub-id-type="pmid">12142567</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Blondeau N, Lauritzen I, Widmann C, Lazdunski M, Heurteaux C. A potent protective role of lysophospholipids against global cerebral ischemia and glutamate excitotoxicity in neuronal cultures. J Cereb Blood Flow Metab. 2002;22(7):821&#x02013;34. 10.1097/00004647-200207000-00007.<pub-id pub-id-type="pmid">12142567</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Zha</surname><given-names>F</given-names></name><name><surname>Shan</surname><given-names>L</given-names></name><etal/></person-group><article-title>Lysophosphatidylcholines and phosphatidylcholines as biomarkers for stroke recovery</article-title><source>Front Neurol</source><year>2022</year><volume>15</volume><issue>13</issue><fpage>1047101</fpage><pub-id pub-id-type="doi">10.3389/fneur.2022.1047101</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Huang M, Xu S, Zhou M, Luo J, Zha F, Shan L, et al. Lysophosphatidylcholines and phosphatidylcholines as biomarkers for stroke recovery. Front Neurol. 2022;15(13):1047101. 10.3389/fneur.2022.1047101.</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Oh</surname><given-names>K</given-names></name><name><surname>Koh</surname><given-names>SB</given-names></name><name><surname>Seo</surname><given-names>WK</given-names></name></person-group><article-title>High free fatty acid level is associated with recurrent stroke in cardioembolic stroke patients</article-title><source>Neurology</source><year>2014</year><volume>82</volume><issue>13</issue><fpage>1142</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000264</pub-id><pub-id pub-id-type="pmid">24587477</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Choi JY, Kim JS, Kim JH, Oh K, Koh SB, Seo WK. High free fatty acid level is associated with recurrent stroke in cardioembolic stroke patients. Neurology. 2014;82(13):1142&#x02013;8. 10.1212/WNL.0000000000000264.<pub-id pub-id-type="pmid">24587477</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>WK</given-names></name><name><surname>Jo</surname><given-names>G</given-names></name><name><surname>Shin</surname><given-names>MJ</given-names></name><name><surname>Oh</surname><given-names>K</given-names></name></person-group><article-title>Medium-chain acylcarnitines are associated with cardioembolic stroke and stroke recurrence</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2018</year><volume>38</volume><issue>9</issue><fpage>2245</fpage><lpage>2253</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.118.311373</pub-id><pub-id pub-id-type="pmid">30026276</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Seo WK, Jo G, Shin MJ, Oh K. Medium-chain acylcarnitines are associated with cardioembolic stroke and stroke recurrence. Arterioscler Thromb Vasc Biol. 2018;38(9):2245&#x02013;53. 10.1161/ATVBAHA.118.311373.<pub-id pub-id-type="pmid">30026276</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Au</surname><given-names>A</given-names></name></person-group><article-title>Metabolomics and lipidomics of ischemic stroke</article-title><source>Adv Clin Chem</source><year>2018</year><volume>85</volume><fpage>31</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/bs.acc.2018.02.002</pub-id><pub-id pub-id-type="pmid">29655461</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Au A. Metabolomics and lipidomics of ischemic stroke. Adv Clin Chem. 2018;85:31&#x02013;69. 10.1016/bs.acc.2018.02.002.<pub-id pub-id-type="pmid">29655461</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Piao</surname><given-names>X</given-names></name></person-group><article-title>Discovery of a new biomarker pattern for differential diagnosis of acute ischemic stroke using targeted metabolomics</article-title><source>Front Neurol</source><year>2019</year><volume>19</volume><issue>10</issue><fpage>1011</fpage><pub-id pub-id-type="doi">10.3389/fneur.2019.01011</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Sun R, Li Y, Cai M, Cao Y, Piao X. Discovery of a new biomarker pattern for differential diagnosis of acute ischemic stroke using targeted metabolomics. Front Neurol. 2019;19(10):1011. 10.3389/fneur.2019.01011.</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Guasch-Ferr&#x000e9;</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Ruiz-Canela</surname><given-names>M</given-names></name><name><surname>Hruby</surname><given-names>A</given-names></name><name><surname>Mart&#x000ed;nez-Gonz&#x000e1;lez</surname><given-names>MA</given-names></name><name><surname>Clish</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Plasma acylcarnitines and risk of cardiovascular disease: effect of Mediterranean diet interventions</article-title><source>Am J Clin Nutr</source><year>2016</year><volume>103</volume><issue>6</issue><fpage>1408</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.3945/ajcn.116.130492</pub-id><pub-id pub-id-type="pmid">27099249</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Guasch-Ferr&#x000e9; M, Zheng Y, Ruiz-Canela M, Hruby A, Mart&#x000ed;nez-Gonz&#x000e1;lez MA, Clish CB, et al. Plasma acylcarnitines and risk of cardiovascular disease: effect of Mediterranean diet interventions. Am J Clin Nutr. 2016;103(6):1408&#x02013;16. 10.3945/ajcn.116.130492.<pub-id pub-id-type="pmid">27099249</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Meikle</surname><given-names>PJ</given-names></name><name><surname>Wong</surname><given-names>G</given-names></name><name><surname>Tsorotes</surname><given-names>D</given-names></name><name><surname>Barlow</surname><given-names>CK</given-names></name><name><surname>Weir</surname><given-names>JM</given-names></name><name><surname>Christopher</surname><given-names>MJ</given-names></name><name><surname>MacIntosh</surname><given-names>GL</given-names></name><name><surname>Goudey</surname><given-names>B</given-names></name><name><surname>Stern</surname><given-names>L</given-names></name><name><surname>Kowalczyk</surname><given-names>A</given-names></name><name><surname>Haviv</surname><given-names>I</given-names></name><name><surname>White</surname><given-names>AJ</given-names></name><name><surname>Dart</surname><given-names>AM</given-names></name><name><surname>Duffy</surname><given-names>SJ</given-names></name><name><surname>Jennings</surname><given-names>GL</given-names></name><name><surname>Kingwell</surname><given-names>BA</given-names></name></person-group><article-title>Plasma lipidomic analysis of stable and unstable coronary artery disease</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2011</year><volume>31</volume><issue>11</issue><fpage>2723</fpage><lpage>2732</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.111.234096</pub-id><pub-id pub-id-type="pmid">21903946</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Meikle PJ, Wong G, Tsorotes D, Barlow CK, Weir JM, Christopher MJ, MacIntosh GL, Goudey B, Stern L, Kowalczyk A, Haviv I, White AJ, Dart AM, Duffy SJ, Jennings GL, Kingwell BA. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler Thromb Vasc Biol. 2011;31(11):2723&#x02013;32. 10.1161/ATVBAHA.111.234096.<pub-id pub-id-type="pmid">21903946</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Petkevicius</surname><given-names>K</given-names></name><name><surname>Virtue</surname><given-names>S</given-names></name><name><surname>Bidault</surname><given-names>G</given-names></name><name><surname>Jenkins</surname><given-names>B</given-names></name><name><surname>&#x000c7;ubuk</surname><given-names>C</given-names></name><name><surname>Morgantini</surname><given-names>C</given-names></name><etal/></person-group><article-title>Accelerated phosphatidylcholine turnover in macrophages promotes adipose tissue inflammation in obesity</article-title><source>Elife</source><year>2019</year><volume>16</volume><issue>8</issue><fpage>e47990</fpage><pub-id pub-id-type="doi">10.7554/eLife.47990</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Petkevicius K, Virtue S, Bidault G, Jenkins B, &#x000c7;ubuk C, Morgantini C, et al. Accelerated phosphatidylcholine turnover in macrophages promotes adipose tissue inflammation in obesity. Elife. 2019;16(8):e47990. 10.7554/eLife.47990.</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name></person-group><article-title>The mechanisms of lysophosphatidylcholine in the development of diseases</article-title><source>Life Sci</source><year>2020</year><volume>15</volume><issue>247</issue><fpage>117443</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.117443</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Liu P, Zhu W, Chen C, Yan B, Zhu L, Chen X, Peng C. The mechanisms of lysophosphatidylcholine in the development of diseases. Life Sci. 2020;15(247):117443. 10.1016/j.lfs.2020.117443.</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Czubowicz</surname><given-names>K</given-names></name><name><surname>J&#x00119;&#x0015b;ko</surname><given-names>H</given-names></name><name><surname>Wencel</surname><given-names>P</given-names></name><name><surname>Lukiw</surname><given-names>WJ</given-names></name><name><surname>Strosznajder</surname><given-names>RP</given-names></name></person-group><article-title>The role of ceramide and sphingosine-1-phosphate in Alzheimer&#x02019;s disease and other neurodegenerative disorders</article-title><source>Mol Neurobiol</source><year>2019</year><volume>56</volume><issue>8</issue><fpage>5455</fpage><pub-id pub-id-type="doi">10.1007/s12035-018-1448-3</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Czubowicz K, J&#x00119;&#x0015b;ko H, Wencel P, Lukiw WJ, Strosznajder RP. The role of ceramide and sphingosine-1-phosphate in Alzheimer&#x02019;s disease and other neurodegenerative disorders. Mol Neurobiol. 2019;56(8):5455. 10.1007/s12035-018-1448-3.</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>SC</given-names></name><name><surname>Kim</surname><given-names>BR</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Park</surname><given-names>TS</given-names></name></person-group><article-title>Sphingolipid metabolism and obesity-induced inflammation</article-title><source>Front Endocrinol (Lausanne)</source><year>2013</year><volume>4</volume><issue>4</issue><fpage>67</fpage><pub-id pub-id-type="doi">10.3389/fendo.2013.00067</pub-id><pub-id pub-id-type="pmid">23761785</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Kang SC, Kim BR, Lee SY, Park TS. Sphingolipid metabolism and obesity-induced inflammation. Front Endocrinol (Lausanne). 2013;4(4):67. 10.3389/fendo.2013.00067.<pub-id pub-id-type="pmid">23761785</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Capodivento</surname><given-names>G</given-names></name><name><surname>De Michelis</surname><given-names>C</given-names></name><name><surname>Carpo</surname><given-names>M</given-names></name><name><surname>Fancellu</surname><given-names>R</given-names></name><name><surname>Schirinzi</surname><given-names>E</given-names></name><name><surname>Severi</surname><given-names>D</given-names></name><etal/></person-group><article-title>CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2021</year><volume>92</volume><issue>3</issue><fpage>303</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2020-324445</pub-id><pub-id pub-id-type="pmid">33093191</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Capodivento G, De Michelis C, Carpo M, Fancellu R, Schirinzi E, Severi D, et al. CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS. J Neurol Neurosurg Psychiatry. 2021;92(3):303&#x02013;10. 10.1136/jnnp-2020-324445.<pub-id pub-id-type="pmid">33093191</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>S</given-names></name><name><surname>Hori</surname><given-names>M</given-names></name><name><surname>Hagiwara</surname><given-names>A</given-names></name><name><surname>Tsurushima</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Maehara</surname><given-names>T</given-names></name><etal/></person-group><article-title>Myelin and axonal damage in normal-appearing white matter in patients with moyamoya disease</article-title><source>AJNR Am J Neuroradiol</source><year>2020</year><volume>41</volume><issue>9</issue><fpage>1618</fpage><lpage>1624</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A6708</pub-id><pub-id pub-id-type="pmid">32855183</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Hara S, Hori M, Hagiwara A, Tsurushima Y, Tanaka Y, Maehara T, et al. Myelin and axonal damage in normal-appearing white matter in patients with moyamoya disease. AJNR Am J Neuroradiol. 2020;41(9):1618&#x02013;24. 10.3174/ajnr.A6708.<pub-id pub-id-type="pmid">32855183</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Ghidoni</surname><given-names>R</given-names></name><name><surname>Caretti</surname><given-names>A</given-names></name><name><surname>Signorelli</surname><given-names>P</given-names></name></person-group><article-title>Role of sphingolipids in the pathobiology of lung inflammation</article-title><source>Mediators Inflamm</source><year>2015</year><volume>2015</volume><fpage>487508</fpage><pub-id pub-id-type="doi">10.1155/2015/487508</pub-id><pub-id pub-id-type="pmid">26770018</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Ghidoni R, Caretti A, Signorelli P. Role of sphingolipids in the pathobiology of lung inflammation. Mediators Inflamm. 2015;2015:487508. 10.1155/2015/487508.<pub-id pub-id-type="pmid">26770018</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Gulati</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Munkacsi</surname><given-names>AB</given-names></name><name><surname>Wilcox</surname><given-names>L</given-names></name><name><surname>Sturley</surname><given-names>SL</given-names></name></person-group><article-title>Sterols and sphingolipids: dynamic duo or partners in crime?</article-title><source>Prog Lipid Res</source><year>2010</year><volume>49</volume><issue>4</issue><fpage>353</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/j.plipres.2010.03.003</pub-id><pub-id pub-id-type="pmid">20362613</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Gulati S, Liu Y, Munkacsi AB, Wilcox L, Sturley SL. Sterols and sphingolipids: dynamic duo or partners in crime? Prog Lipid Res. 2010;49(4):353&#x02013;65. 10.1016/j.plipres.2010.03.003.<pub-id pub-id-type="pmid">20362613</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>CY</given-names></name><name><surname>Chang</surname><given-names>ET</given-names></name><name><surname>Cruz</surname><given-names>JC</given-names></name><name><surname>Levesque</surname><given-names>MC</given-names></name><name><surname>Chang</surname><given-names>TY</given-names></name></person-group><article-title>Recombinant acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) purified to essential homogeneity utilizes cholesterol in mixed micelles or in vesicles in a highly cooperative manner</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><issue>52</issue><fpage>35132</fpage><lpage>35141</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.52.35132</pub-id><pub-id pub-id-type="pmid">9857049</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Chang CC, Lee CY, Chang ET, Cruz JC, Levesque MC, Chang TY. Recombinant acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) purified to essential homogeneity utilizes cholesterol in mixed micelles or in vesicles in a highly cooperative manner. J Biol Chem. 1998;273(52):35132&#x02013;41. 10.1074/jbc.273.52.35132.<pub-id pub-id-type="pmid">9857049</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Pitk&#x000e4;nen</surname><given-names>AS</given-names></name><name><surname>Halonen</surname><given-names>TO</given-names></name><name><surname>Kilpel&#x000e4;inen</surname><given-names>HO</given-names></name><name><surname>Riekkinen</surname><given-names>PJ</given-names></name></person-group><article-title>Cholesterol esterase activity in cerebrospinal fluid of multiple sclerosis patients</article-title><source>J Neurol Sci</source><year>1986</year><volume>74</volume><issue>1</issue><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/0022-510x(86)90190-5</pub-id><pub-id pub-id-type="pmid">3723135</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Pitk&#x000e4;nen AS, Halonen TO, Kilpel&#x000e4;inen HO, Riekkinen PJ. Cholesterol esterase activity in cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci. 1986;74(1):45&#x02013;53. 10.1016/0022-510x(86)90190-5.<pub-id pub-id-type="pmid">3723135</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Cutler</surname><given-names>RG</given-names></name><name><surname>Pedersen</surname><given-names>WA</given-names></name><name><surname>Camandola</surname><given-names>S</given-names></name><name><surname>Rothstein</surname><given-names>JD</given-names></name><name><surname>Mattson</surname><given-names>MP</given-names></name></person-group><article-title>Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis</article-title><source>Ann Neurol</source><year>2002</year><volume>52</volume><issue>4</issue><fpage>448</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1002/ana.10312</pub-id><pub-id pub-id-type="pmid">12325074</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002;52(4):448&#x02013;57. 10.1002/ana.10312.<pub-id pub-id-type="pmid">12325074</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Gerl</surname><given-names>MJ</given-names></name><name><surname>Vaz</surname><given-names>WLC</given-names></name><name><surname>Domingues</surname><given-names>N</given-names></name><name><surname>Klose</surname><given-names>C</given-names></name><name><surname>Surma</surname><given-names>MA</given-names></name><name><surname>Sampaio</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Cholesterol is inefficiently converted to cholesteryl esters in the blood of cardiovascular disease patients</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>14764</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-33116-4</pub-id><pub-id pub-id-type="pmid">30282999</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Gerl MJ, Vaz WLC, Domingues N, Klose C, Surma MA, Sampaio JL, et al. Cholesterol is inefficiently converted to cholesteryl esters in the blood of cardiovascular disease patients. Sci Rep. 2018;8(1):14764. 10.1038/s41598-018-33116-4.<pub-id pub-id-type="pmid">30282999</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>E</given-names></name><name><surname>Kantharidis</surname><given-names>P</given-names></name><name><surname>Cooper</surname><given-names>ME</given-names></name><name><surname>Godson</surname><given-names>C</given-names></name></person-group><article-title>Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function</article-title><source>Nat Rev Nephrol</source><year>2021</year><volume>17</volume><issue>11</issue><fpage>725</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1038/s41581-021-00454-y</pub-id><pub-id pub-id-type="pmid">34282342</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Brennan E, Kantharidis P, Cooper ME, Godson C. Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. Nat Rev Nephrol. 2021;17(11):725&#x02013;39. 10.1038/s41581-021-00454-y.<pub-id pub-id-type="pmid">34282342</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Habib</surname><given-names>A</given-names></name><name><surname>Chokr</surname><given-names>D</given-names></name><name><surname>Wan</surname><given-names>J</given-names></name><name><surname>Hegde</surname><given-names>P</given-names></name><name><surname>Mabire</surname><given-names>M</given-names></name><name><surname>Siebert</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver</article-title><source>Gut</source><year>2019</year><volume>68</volume><issue>3</issue><fpage>522</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2018-316137</pub-id><pub-id pub-id-type="pmid">30301768</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Habib A, Chokr D, Wan J, Hegde P, Mabire M, Siebert M, et al. Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver. Gut. 2019;68(3):522&#x02013;32. 10.1136/gutjnl-2018-316137.<pub-id pub-id-type="pmid">30301768</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Dinh</surname><given-names>TP</given-names></name><name><surname>Carpenter</surname><given-names>D</given-names></name><name><surname>Leslie</surname><given-names>FM</given-names></name><name><surname>Freund</surname><given-names>TF</given-names></name><name><surname>Katona</surname><given-names>I</given-names></name><name><surname>Sensi</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Brain monoglyceride lipase participating in endocannabinoid inactivation</article-title><source>Proc Natl Acad Sci U S A</source><year>2002</year><volume>99</volume><issue>16</issue><fpage>10819</fpage><lpage>10824</lpage><pub-id pub-id-type="doi">10.1073/pnas.152334899</pub-id><pub-id pub-id-type="pmid">12136125</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A. 2002;99(16):10819&#x02013;24. 10.1073/pnas.152334899.<pub-id pub-id-type="pmid">12136125</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Nomura</surname><given-names>DK</given-names></name><name><surname>Morrison</surname><given-names>BE</given-names></name><name><surname>Blankman</surname><given-names>JL</given-names></name><name><surname>Long</surname><given-names>JZ</given-names></name><name><surname>Kinsey</surname><given-names>SG</given-names></name><name><surname>Marcondes</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation</article-title><source>Science</source><year>2011</year><volume>334</volume><issue>6057</issue><fpage>809</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1126/science.1209200</pub-id><pub-id pub-id-type="pmid">22021672</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science. 2011;334(6057):809&#x02013;13. 10.1126/science.1209200.<pub-id pub-id-type="pmid">22021672</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Enzymatic synthesis of extremely pure triacylglycerols enriched in conjugated linoleic acids</article-title><source>Molecules</source><year>2013</year><volume>18</volume><issue>8</issue><fpage>9704</fpage><lpage>9716</lpage><pub-id pub-id-type="doi">10.3390/molecules18089704</pub-id><pub-id pub-id-type="pmid">23945644</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Cao Y, Wang W, Xu Y, Yang B, Wang Y. Enzymatic synthesis of extremely pure triacylglycerols enriched in conjugated linoleic acids. Molecules. 2013;18(8):9704&#x02013;16. 10.3390/molecules18089704.<pub-id pub-id-type="pmid">23945644</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Camerer</surname><given-names>E</given-names></name></person-group><article-title>Endotoxemia rocks sphingolipid metabolism at the blood-brain barrier: an Editorial Highlight for &#x02018;Alteration of sphingolipid metabolism as a putative mechanism underlying LPS-induced BBB disruption&#x02019; on page 172</article-title><source>J Neurochem</source><year>2018</year><volume>144</volume><issue>2</issue><fpage>115</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1111/jnc.14246</pub-id><pub-id pub-id-type="pmid">29285771</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Camerer E. Endotoxemia rocks sphingolipid metabolism at the blood-brain barrier: an Editorial Highlight for &#x02018;Alteration of sphingolipid metabolism as a putative mechanism underlying LPS-induced BBB disruption&#x02019; on page 172. J Neurochem. 2018;144(2):115&#x02013;7. 10.1111/jnc.14246.<pub-id pub-id-type="pmid">29285771</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Narducci</surname><given-names>A</given-names></name><name><surname>Yasuyuki</surname><given-names>K</given-names></name><name><surname>Onken</surname><given-names>J</given-names></name><name><surname>Blecharz</surname><given-names>K</given-names></name><name><surname>Vajkoczy</surname><given-names>P</given-names></name></person-group><article-title>In vivo demonstration of blood-brain barrier impairment in moyamoya disease</article-title><source>Acta Neurochir (Wien)</source><year>2019</year><volume>161</volume><issue>2</issue><fpage>371</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1007/s00701-019-03811-w</pub-id><pub-id pub-id-type="pmid">30675657</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Narducci A, Yasuyuki K, Onken J, Blecharz K, Vajkoczy P. In vivo demonstration of blood-brain barrier impairment in moyamoya disease. Acta Neurochir (Wien). 2019;161(2):371&#x02013;8. 10.1007/s00701-019-03811-w.<pub-id pub-id-type="pmid">30675657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>van Meer</surname><given-names>G</given-names></name><name><surname>Voelker</surname><given-names>DR</given-names></name><name><surname>Feigenson</surname><given-names>GW</given-names></name></person-group><article-title>Membrane lipids: where they are and how they behave</article-title><source>Nat Rev Mol Cell Biol</source><year>2008</year><volume>9</volume><issue>2</issue><fpage>112</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/nrm2330</pub-id><pub-id pub-id-type="pmid">18216768</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008;9(2):112&#x02013;24. 10.1038/nrm2330.<pub-id pub-id-type="pmid">18216768</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Chiurchi&#x000f9;</surname><given-names>V</given-names></name><name><surname>Leuti</surname><given-names>A</given-names></name><name><surname>Maccarrone</surname><given-names>M</given-names></name></person-group><article-title>Bioactive lipids and chronic inflammation: managing the fire within</article-title><source>Front Immunol</source><year>2018</year><volume>29</volume><issue>9</issue><fpage>38</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00038</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Chiurchi&#x000f9; V, Leuti A, Maccarrone M. Bioactive lipids and chronic inflammation: managing the fire within. Front Immunol. 2018;29(9):38. 10.3389/fimmu.2018.00038.</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Rasul</surname><given-names>A</given-names></name><name><surname>Anwar</surname><given-names>H</given-names></name><name><surname>Imran</surname><given-names>A</given-names></name><name><surname>Qasim</surname><given-names>M</given-names></name><etal/></person-group><article-title>Role of cholesterol and sphingolipids in brain development and neurological diseases</article-title><source>Lipids Health Dis</source><year>2019</year><volume>18</volume><issue>1</issue><fpage>26</fpage><pub-id pub-id-type="doi">10.1186/s12944-019-0965-z</pub-id><pub-id pub-id-type="pmid">30683111</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Hussain G, Wang J, Rasul A, Anwar H, Imran A, Qasim M, et al. Role of cholesterol and sphingolipids in brain development and neurological diseases. Lipids Health Dis. 2019;18(1):26. 10.1186/s12944-019-0965-z.<pub-id pub-id-type="pmid">30683111</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>van Kruining</surname><given-names>D</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>van Echten-Deckert</surname><given-names>G</given-names></name><name><surname>Mielke</surname><given-names>MM</given-names></name><name><surname>Bowman</surname><given-names>A</given-names></name><name><surname>Ellis</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sphingolipids as prognostic biomarkers of neurodegeneration, neuroinflammation, and psychiatric diseases and their emerging role in lipidomic investigation methods</article-title><source>Adv Drug Deliv Rev</source><year>2020</year><volume>159</volume><fpage>232</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.04.009</pub-id><pub-id pub-id-type="pmid">32360155</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">van Kruining D, Luo Q, van Echten-Deckert G, Mielke MM, Bowman A, Ellis S, et al. Sphingolipids as prognostic biomarkers of neurodegeneration, neuroinflammation, and psychiatric diseases and their emerging role in lipidomic investigation methods. Adv Drug Deliv Rev. 2020;159:232&#x02013;44. 10.1016/j.addr.2020.04.009.<pub-id pub-id-type="pmid">32360155</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>M</given-names></name><name><surname>Melo</surname><given-names>T</given-names></name><name><surname>Maur&#x000ed;cio</surname><given-names>T</given-names></name><name><surname>Ferreira</surname><given-names>H</given-names></name><name><surname>Domingues</surname><given-names>P</given-names></name><name><surname>Domingues</surname><given-names>R</given-names></name></person-group><article-title>The non-enzymatic oxidation of phosphatidylethanolamine and phosphatidylserine and their intriguing roles in inflammation dynamics and diseases</article-title><source>FEBS Lett</source><year>2024</year><volume>598</volume><issue>17</issue><fpage>2174</fpage><lpage>2189</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.14992</pub-id><pub-id pub-id-type="pmid">39097985</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Santos M, Melo T, Maur&#x000ed;cio T, Ferreira H, Domingues P, Domingues R. The non-enzymatic oxidation of phosphatidylethanolamine and phosphatidylserine and their intriguing roles in inflammation dynamics and diseases. FEBS Lett. 2024;598(17):2174&#x02013;89. 10.1002/1873-3468.14992.<pub-id pub-id-type="pmid">39097985</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>van der Veen</surname><given-names>JN</given-names></name><name><surname>Kennelly</surname><given-names>JP</given-names></name><name><surname>Wan</surname><given-names>S</given-names></name><name><surname>Vance</surname><given-names>JE</given-names></name><name><surname>Vance</surname><given-names>DE</given-names></name><name><surname>Jacobs</surname><given-names>RL</given-names></name></person-group><article-title>The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease</article-title><source>Biochim Biophys Acta Biomembr</source><year>2017</year><volume>1859</volume><issue>9 Pt B</issue><fpage>1558</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2017.04.006</pub-id><pub-id pub-id-type="pmid">28411170</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">van der Veen JN, Kennelly JP, Wan S, Vance JE, Vance DE, Jacobs RL. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim Biophys Acta Biomembr. 2017;1859(9 Pt B):1558&#x02013;72. 10.1016/j.bbamem.2017.04.006.<pub-id pub-id-type="pmid">28411170</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>